recordname	recordmodel	genename	rsid	geno	catagrory	reference	recordlabel	recordeffect	description	diseaseCatagrory
家族性地中海热	常染色体隐性	MEFV	rs104895097	C/C	正常基因型	Bernot A， et al. Non-founder mutations in the MEFV gene establish this gene as the cause of familial Mediterranean fever (FMF). 1998Villani AC， et al. Genetic variation in the familial Mediterranean fever gene (MEFV) and risk for Crohn's disease and ulcerative colitis. 2009Feng J， et al. Missense mutations in the MEFV gene are associated with fibromyalgia syndrome and correlate with elevated IL-1beta plasma levels. 2009Aksentijevich I， et al. Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population. 1999Cazeneuve C， et al. MEFV-Gene analysis in armenian patients with Familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications. 1999Sugiura T， et al. Familial Mediterranean fever in three Japanese patients， and a comparison of the frequency of MEFV gene mutations in Japanese and Mediterranean populations. 2007Ryan JG， et al. Clinical features and functional significance of the P369S/R408Q variant in pyrin， the familial Mediterranean fever protein. 2010Ulane RE， et al. A rapid accurate assay for choline kinase. 1977Oshima K， et al. A case of familial Mediterranean fever associated with compound heterozygosity for the pyrin variant L110P-E148Q/M680I in Japan. 2010Medlej-Hashim M， et al. 1Novel MEFV transcripts in Familial Mediterranean fever patients and controls. 2010Fil'shtinski? AIa， et al. [X-ray assessment of the motor-evacuatory function of the gastrointestinal tract in the diagnosis of the dumping-syndrome]. 1976Booth DR， et al. Pyrin/marenostrin mutations in familial Mediterranean fever. 1998Ben-Chetrit E， et al. The E148Q mutation in the MEFV gene: is it a disease-causing mutation or a sequence variant? 2000Cazeneuve C， et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. 2000Dodé C， et al. Mutational spectrum in the MEFV and TNFRSF1A genes in patients suffering from AA amyloidosis and recurrent inflammatory attacks. 2002Belmahi L， et al. Prevalence and distribution of MEFV mutations among Arabs from the Maghreb patients suffering from familial Mediterranean fever. 2006Nakano K， et al. Possible intervention of insulin， cyclic AMP， and glucocorticoids in protein-sparing action of dietary carbohydrate in rats. 1975Tchernitchko D， et al. Clinical evaluation of a reverse hybridization assay for the molecular detection of twelve MEFV gene mutations. 2003Sabbagh AS， et al. MEFV gene mutations spectrum among Lebanese patients referred for Familial Mediterranean Fever work-up: experience of a major tertiary care center. 2008Ben-Chetrit E， et al. Familial mediterranean Fever in the world. 2009	GENETIC_DISEASE			其他
家族性地中海热	常染色体隐性	MEFV	rs104895097	C/T	有害突变携带者	Bernot A， et al. Non-founder mutations in the MEFV gene establish this gene as the cause of familial Mediterranean fever (FMF). 1998Villani AC， et al. Genetic variation in the familial Mediterranean fever gene (MEFV) and risk for Crohn's disease and ulcerative colitis. 2009Feng J， et al. Missense mutations in the MEFV gene are associated with fibromyalgia syndrome and correlate with elevated IL-1beta plasma levels. 2009Aksentijevich I， et al. Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population. 1999Cazeneuve C， et al. MEFV-Gene analysis in armenian patients with Familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications. 1999Sugiura T， et al. Familial Mediterranean fever in three Japanese patients， and a comparison of the frequency of MEFV gene mutations in Japanese and Mediterranean populations. 2007Ryan JG， et al. Clinical features and functional significance of the P369S/R408Q variant in pyrin， the familial Mediterranean fever protein. 2010Ulane RE， et al. A rapid accurate assay for choline kinase. 1977Oshima K， et al. A case of familial Mediterranean fever associated with compound heterozygosity for the pyrin variant L110P-E148Q/M680I in Japan. 2010Medlej-Hashim M， et al. 1Novel MEFV transcripts in Familial Mediterranean fever patients and controls. 2010Fil'shtinski? AIa， et al. [X-ray assessment of the motor-evacuatory function of the gastrointestinal tract in the diagnosis of the dumping-syndrome]. 1976Booth DR， et al. Pyrin/marenostrin mutations in familial Mediterranean fever. 1998Ben-Chetrit E， et al. The E148Q mutation in the MEFV gene: is it a disease-causing mutation or a sequence variant? 2000Cazeneuve C， et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. 2000Dodé C， et al. Mutational spectrum in the MEFV and TNFRSF1A genes in patients suffering from AA amyloidosis and recurrent inflammatory attacks. 2002Belmahi L， et al. Prevalence and distribution of MEFV mutations among Arabs from the Maghreb patients suffering from familial Mediterranean fever. 2006Nakano K， et al. Possible intervention of insulin， cyclic AMP， and glucocorticoids in protein-sparing action of dietary carbohydrate in rats. 1975Tchernitchko D， et al. Clinical evaluation of a reverse hybridization assay for the molecular detection of twelve MEFV gene mutations. 2003Sabbagh AS， et al. MEFV gene mutations spectrum among Lebanese patients referred for Familial Mediterranean Fever work-up: experience of a major tertiary care center. 2008Ben-Chetrit E， et al. Familial mediterranean Fever in the world. 2009	GENETIC_DISEASE			其他
家族性地中海热	常染色体隐性	MEFV	rs104895097	T/T	有害突变纯合	Bernot A， et al. Non-founder mutations in the MEFV gene establish this gene as the cause of familial Mediterranean fever (FMF). 1998Villani AC， et al. Genetic variation in the familial Mediterranean fever gene (MEFV) and risk for Crohn's disease and ulcerative colitis. 2009Feng J， et al. Missense mutations in the MEFV gene are associated with fibromyalgia syndrome and correlate with elevated IL-1beta plasma levels. 2009Aksentijevich I， et al. Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population. 1999Cazeneuve C， et al. MEFV-Gene analysis in armenian patients with Familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications. 1999Sugiura T， et al. Familial Mediterranean fever in three Japanese patients， and a comparison of the frequency of MEFV gene mutations in Japanese and Mediterranean populations. 2007Ryan JG， et al. Clinical features and functional significance of the P369S/R408Q variant in pyrin， the familial Mediterranean fever protein. 2010Ulane RE， et al. A rapid accurate assay for choline kinase. 1977Oshima K， et al. A case of familial Mediterranean fever associated with compound heterozygosity for the pyrin variant L110P-E148Q/M680I in Japan. 2010Medlej-Hashim M， et al. 1Novel MEFV transcripts in Familial Mediterranean fever patients and controls. 2010Fil'shtinski? AIa， et al. [X-ray assessment of the motor-evacuatory function of the gastrointestinal tract in the diagnosis of the dumping-syndrome]. 1976Booth DR， et al. Pyrin/marenostrin mutations in familial Mediterranean fever. 1998Ben-Chetrit E， et al. The E148Q mutation in the MEFV gene: is it a disease-causing mutation or a sequence variant? 2000Cazeneuve C， et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. 2000Dodé C， et al. Mutational spectrum in the MEFV and TNFRSF1A genes in patients suffering from AA amyloidosis and recurrent inflammatory attacks. 2002Belmahi L， et al. Prevalence and distribution of MEFV mutations among Arabs from the Maghreb patients suffering from familial Mediterranean fever. 2006Nakano K， et al. Possible intervention of insulin， cyclic AMP， and glucocorticoids in protein-sparing action of dietary carbohydrate in rats. 1975Tchernitchko D， et al. Clinical evaluation of a reverse hybridization assay for the molecular detection of twelve MEFV gene mutations. 2003Sabbagh AS， et al. MEFV gene mutations spectrum among Lebanese patients referred for Familial Mediterranean Fever work-up: experience of a major tertiary care center. 2008Ben-Chetrit E， et al. Familial mediterranean Fever in the world. 2009	GENETIC_DISEASE			其他
家族性地中海热	常染色体隐性	MEFV	rs11466023	A/G	有害突变携带者	Bernot A， et al. Non-founder mutations in the MEFV gene establish this gene as the cause of familial Mediterranean fever (FMF). 1998Villani AC， et al. Genetic variation in the familial Mediterranean fever gene (MEFV) and risk for Crohn's disease and ulcerative colitis. 2009Feng J， et al. Missense mutations in the MEFV gene are associated with fibromyalgia syndrome and correlate with elevated IL-1beta plasma levels. 2009Aksentijevich I， et al. Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population. 1999Cazeneuve C， et al. MEFV-Gene analysis in armenian patients with Familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications. 1999Sugiura T， et al. Familial Mediterranean fever in three Japanese patients， and a comparison of the frequency of MEFV gene mutations in Japanese and Mediterranean populations. 2007Ryan JG， et al. Clinical features and functional significance of the P369S/R408Q variant in pyrin， the familial Mediterranean fever protein. 2010Ulane RE， et al. A rapid accurate assay for choline kinase. 1977Oshima K， et al. A case of familial Mediterranean fever associated with compound heterozygosity for the pyrin variant L110P-E148Q/M680I in Japan. 2010Medlej-Hashim M， et al. 1Novel MEFV transcripts in Familial Mediterranean fever patients and controls. 2010Fil'shtinski? AIa， et al. [X-ray assessment of the motor-evacuatory function of the gastrointestinal tract in the diagnosis of the dumping-syndrome]. 1976Booth DR， et al. Pyrin/marenostrin mutations in familial Mediterranean fever. 1998Ben-Chetrit E， et al. The E148Q mutation in the MEFV gene: is it a disease-causing mutation or a sequence variant? 2000Cazeneuve C， et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. 2000Dodé C， et al. Mutational spectrum in the MEFV and TNFRSF1A genes in patients suffering from AA amyloidosis and recurrent inflammatory attacks. 2002Belmahi L， et al. Prevalence and distribution of MEFV mutations among Arabs from the Maghreb patients suffering from familial Mediterranean fever. 2006Nakano K， et al. Possible intervention of insulin， cyclic AMP， and glucocorticoids in protein-sparing action of dietary carbohydrate in rats. 1975Tchernitchko D， et al. Clinical evaluation of a reverse hybridization assay for the molecular detection of twelve MEFV gene mutations. 2003Sabbagh AS， et al. MEFV gene mutations spectrum among Lebanese patients referred for Familial Mediterranean Fever work-up: experience of a major tertiary care center. 2008Ben-Chetrit E， et al. Familial mediterranean Fever in the world. 2009	GENETIC_DISEASE			其他
家族性地中海热	常染色体隐性	MEFV	rs11466023	G/G	正常基因型	Bernot A， et al. Non-founder mutations in the MEFV gene establish this gene as the cause of familial Mediterranean fever (FMF). 1998Villani AC， et al. Genetic variation in the familial Mediterranean fever gene (MEFV) and risk for Crohn's disease and ulcerative colitis. 2009Feng J， et al. Missense mutations in the MEFV gene are associated with fibromyalgia syndrome and correlate with elevated IL-1beta plasma levels. 2009Aksentijevich I， et al. Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population. 1999Cazeneuve C， et al. MEFV-Gene analysis in armenian patients with Familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications. 1999Sugiura T， et al. Familial Mediterranean fever in three Japanese patients， and a comparison of the frequency of MEFV gene mutations in Japanese and Mediterranean populations. 2007Ryan JG， et al. Clinical features and functional significance of the P369S/R408Q variant in pyrin， the familial Mediterranean fever protein. 2010Ulane RE， et al. A rapid accurate assay for choline kinase. 1977Oshima K， et al. A case of familial Mediterranean fever associated with compound heterozygosity for the pyrin variant L110P-E148Q/M680I in Japan. 2010Medlej-Hashim M， et al. 1Novel MEFV transcripts in Familial Mediterranean fever patients and controls. 2010Fil'shtinski? AIa， et al. [X-ray assessment of the motor-evacuatory function of the gastrointestinal tract in the diagnosis of the dumping-syndrome]. 1976Booth DR， et al. Pyrin/marenostrin mutations in familial Mediterranean fever. 1998Ben-Chetrit E， et al. The E148Q mutation in the MEFV gene: is it a disease-causing mutation or a sequence variant? 2000Cazeneuve C， et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. 2000Dodé C， et al. Mutational spectrum in the MEFV and TNFRSF1A genes in patients suffering from AA amyloidosis and recurrent inflammatory attacks. 2002Belmahi L， et al. Prevalence and distribution of MEFV mutations among Arabs from the Maghreb patients suffering from familial Mediterranean fever. 2006Nakano K， et al. Possible intervention of insulin， cyclic AMP， and glucocorticoids in protein-sparing action of dietary carbohydrate in rats. 1975Tchernitchko D， et al. Clinical evaluation of a reverse hybridization assay for the molecular detection of twelve MEFV gene mutations. 2003Sabbagh AS， et al. MEFV gene mutations spectrum among Lebanese patients referred for Familial Mediterranean Fever work-up: experience of a major tertiary care center. 2008Ben-Chetrit E， et al. Familial mediterranean Fever in the world. 2009	GENETIC_DISEASE			其他
家族性地中海热	常染色体隐性	MEFV	rs11466023	A/A	有害突变纯合	Bernot A， et al. Non-founder mutations in the MEFV gene establish this gene as the cause of familial Mediterranean fever (FMF). 1998Villani AC， et al. Genetic variation in the familial Mediterranean fever gene (MEFV) and risk for Crohn's disease and ulcerative colitis. 2009Feng J， et al. Missense mutations in the MEFV gene are associated with fibromyalgia syndrome and correlate with elevated IL-1beta plasma levels. 2009Aksentijevich I， et al. Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population. 1999Cazeneuve C， et al. MEFV-Gene analysis in armenian patients with Familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications. 1999Sugiura T， et al. Familial Mediterranean fever in three Japanese patients， and a comparison of the frequency of MEFV gene mutations in Japanese and Mediterranean populations. 2007Ryan JG， et al. Clinical features and functional significance of the P369S/R408Q variant in pyrin， the familial Mediterranean fever protein. 2010Ulane RE， et al. A rapid accurate assay for choline kinase. 1977Oshima K， et al. A case of familial Mediterranean fever associated with compound heterozygosity for the pyrin variant L110P-E148Q/M680I in Japan. 2010Medlej-Hashim M， et al. 1Novel MEFV transcripts in Familial Mediterranean fever patients and controls. 2010Fil'shtinski? AIa， et al. [X-ray assessment of the motor-evacuatory function of the gastrointestinal tract in the diagnosis of the dumping-syndrome]. 1976Booth DR， et al. Pyrin/marenostrin mutations in familial Mediterranean fever. 1998Ben-Chetrit E， et al. The E148Q mutation in the MEFV gene: is it a disease-causing mutation or a sequence variant? 2000Cazeneuve C， et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. 2000Dodé C， et al. Mutational spectrum in the MEFV and TNFRSF1A genes in patients suffering from AA amyloidosis and recurrent inflammatory attacks. 2002Belmahi L， et al. Prevalence and distribution of MEFV mutations among Arabs from the Maghreb patients suffering from familial Mediterranean fever. 2006Nakano K， et al. Possible intervention of insulin， cyclic AMP， and glucocorticoids in protein-sparing action of dietary carbohydrate in rats. 1975Tchernitchko D， et al. Clinical evaluation of a reverse hybridization assay for the molecular detection of twelve MEFV gene mutations. 2003Sabbagh AS， et al. MEFV gene mutations spectrum among Lebanese patients referred for Familial Mediterranean Fever work-up: experience of a major tertiary care center. 2008Ben-Chetrit E， et al. Familial mediterranean Fever in the world. 2009	GENETIC_DISEASE			其他
家族性地中海热	常染色体隐性	MEFV	rs28940578	C/C	正常基因型	Bernot A， et al. Non-founder mutations in the MEFV gene establish this gene as the cause of familial Mediterranean fever (FMF). 1998Villani AC， et al. Genetic variation in the familial Mediterranean fever gene (MEFV) and risk for Crohn's disease and ulcerative colitis. 2009Feng J， et al. Missense mutations in the MEFV gene are associated with fibromyalgia syndrome and correlate with elevated IL-1beta plasma levels. 2009Aksentijevich I， et al. Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population. 1999Cazeneuve C， et al. MEFV-Gene analysis in armenian patients with Familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications. 1999Sugiura T， et al. Familial Mediterranean fever in three Japanese patients， and a comparison of the frequency of MEFV gene mutations in Japanese and Mediterranean populations. 2007Ryan JG， et al. Clinical features and functional significance of the P369S/R408Q variant in pyrin， the familial Mediterranean fever protein. 2010Ulane RE， et al. A rapid accurate assay for choline kinase. 1977Oshima K， et al. A case of familial Mediterranean fever associated with compound heterozygosity for the pyrin variant L110P-E148Q/M680I in Japan. 2010Medlej-Hashim M， et al. 1Novel MEFV transcripts in Familial Mediterranean fever patients and controls. 2010Fil'shtinski? AIa， et al. [X-ray assessment of the motor-evacuatory function of the gastrointestinal tract in the diagnosis of the dumping-syndrome]. 1976Booth DR， et al. Pyrin/marenostrin mutations in familial Mediterranean fever. 1998Ben-Chetrit E， et al. The E148Q mutation in the MEFV gene: is it a disease-causing mutation or a sequence variant? 2000Cazeneuve C， et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. 2000Dodé C， et al. Mutational spectrum in the MEFV and TNFRSF1A genes in patients suffering from AA amyloidosis and recurrent inflammatory attacks. 2002Belmahi L， et al. Prevalence and distribution of MEFV mutations among Arabs from the Maghreb patients suffering from familial Mediterranean fever. 2006Nakano K， et al. Possible intervention of insulin， cyclic AMP， and glucocorticoids in protein-sparing action of dietary carbohydrate in rats. 1975Tchernitchko D， et al. Clinical evaluation of a reverse hybridization assay for the molecular detection of twelve MEFV gene mutations. 2003Sabbagh AS， et al. MEFV gene mutations spectrum among Lebanese patients referred for Familial Mediterranean Fever work-up: experience of a major tertiary care center. 2008Ben-Chetrit E， et al. Familial mediterranean Fever in the world. 2009	GENETIC_DISEASE			其他
家族性地中海热	常染色体隐性	MEFV	rs28940578	C/T	有害突变携带者	Bernot A， et al. Non-founder mutations in the MEFV gene establish this gene as the cause of familial Mediterranean fever (FMF). 1998Villani AC， et al. Genetic variation in the familial Mediterranean fever gene (MEFV) and risk for Crohn's disease and ulcerative colitis. 2009Feng J， et al. Missense mutations in the MEFV gene are associated with fibromyalgia syndrome and correlate with elevated IL-1beta plasma levels. 2009Aksentijevich I， et al. Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population. 1999Cazeneuve C， et al. MEFV-Gene analysis in armenian patients with Familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications. 1999Sugiura T， et al. Familial Mediterranean fever in three Japanese patients， and a comparison of the frequency of MEFV gene mutations in Japanese and Mediterranean populations. 2007Ryan JG， et al. Clinical features and functional significance of the P369S/R408Q variant in pyrin， the familial Mediterranean fever protein. 2010Ulane RE， et al. A rapid accurate assay for choline kinase. 1977Oshima K， et al. A case of familial Mediterranean fever associated with compound heterozygosity for the pyrin variant L110P-E148Q/M680I in Japan. 2010Medlej-Hashim M， et al. 1Novel MEFV transcripts in Familial Mediterranean fever patients and controls. 2010Fil'shtinski? AIa， et al. [X-ray assessment of the motor-evacuatory function of the gastrointestinal tract in the diagnosis of the dumping-syndrome]. 1976Booth DR， et al. Pyrin/marenostrin mutations in familial Mediterranean fever. 1998Ben-Chetrit E， et al. The E148Q mutation in the MEFV gene: is it a disease-causing mutation or a sequence variant? 2000Cazeneuve C， et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. 2000Dodé C， et al. Mutational spectrum in the MEFV and TNFRSF1A genes in patients suffering from AA amyloidosis and recurrent inflammatory attacks. 2002Belmahi L， et al. Prevalence and distribution of MEFV mutations among Arabs from the Maghreb patients suffering from familial Mediterranean fever. 2006Nakano K， et al. Possible intervention of insulin， cyclic AMP， and glucocorticoids in protein-sparing action of dietary carbohydrate in rats. 1975Tchernitchko D， et al. Clinical evaluation of a reverse hybridization assay for the molecular detection of twelve MEFV gene mutations. 2003Sabbagh AS， et al. MEFV gene mutations spectrum among Lebanese patients referred for Familial Mediterranean Fever work-up: experience of a major tertiary care center. 2008Ben-Chetrit E， et al. Familial mediterranean Fever in the world. 2009	GENETIC_DISEASE			其他
家族性地中海热	常染色体隐性	MEFV	rs28940578	T/T	有害突变纯合	Bernot A， et al. Non-founder mutations in the MEFV gene establish this gene as the cause of familial Mediterranean fever (FMF). 1998Villani AC， et al. Genetic variation in the familial Mediterranean fever gene (MEFV) and risk for Crohn's disease and ulcerative colitis. 2009Feng J， et al. Missense mutations in the MEFV gene are associated with fibromyalgia syndrome and correlate with elevated IL-1beta plasma levels. 2009Aksentijevich I， et al. Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population. 1999Cazeneuve C， et al. MEFV-Gene analysis in armenian patients with Familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications. 1999Sugiura T， et al. Familial Mediterranean fever in three Japanese patients， and a comparison of the frequency of MEFV gene mutations in Japanese and Mediterranean populations. 2007Ryan JG， et al. Clinical features and functional significance of the P369S/R408Q variant in pyrin， the familial Mediterranean fever protein. 2010Ulane RE， et al. A rapid accurate assay for choline kinase. 1977Oshima K， et al. A case of familial Mediterranean fever associated with compound heterozygosity for the pyrin variant L110P-E148Q/M680I in Japan. 2010Medlej-Hashim M， et al. 1Novel MEFV transcripts in Familial Mediterranean fever patients and controls. 2010Fil'shtinski? AIa， et al. [X-ray assessment of the motor-evacuatory function of the gastrointestinal tract in the diagnosis of the dumping-syndrome]. 1976Booth DR， et al. Pyrin/marenostrin mutations in familial Mediterranean fever. 1998Ben-Chetrit E， et al. The E148Q mutation in the MEFV gene: is it a disease-causing mutation or a sequence variant? 2000Cazeneuve C， et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. 2000Dodé C， et al. Mutational spectrum in the MEFV and TNFRSF1A genes in patients suffering from AA amyloidosis and recurrent inflammatory attacks. 2002Belmahi L， et al. Prevalence and distribution of MEFV mutations among Arabs from the Maghreb patients suffering from familial Mediterranean fever. 2006Nakano K， et al. Possible intervention of insulin， cyclic AMP， and glucocorticoids in protein-sparing action of dietary carbohydrate in rats. 1975Tchernitchko D， et al. Clinical evaluation of a reverse hybridization assay for the molecular detection of twelve MEFV gene mutations. 2003Sabbagh AS， et al. MEFV gene mutations spectrum among Lebanese patients referred for Familial Mediterranean Fever work-up: experience of a major tertiary care center. 2008Ben-Chetrit E， et al. Familial mediterranean Fever in the world. 2009	GENETIC_DISEASE			其他
家族性地中海热	常染色体隐性	MEFV	rs28940580	C/C	正常基因型	Bernot A， et al. Non-founder mutations in the MEFV gene establish this gene as the cause of familial Mediterranean fever (FMF). 1998Villani AC， et al. Genetic variation in the familial Mediterranean fever gene (MEFV) and risk for Crohn's disease and ulcerative colitis. 2009Feng J， et al. Missense mutations in the MEFV gene are associated with fibromyalgia syndrome and correlate with elevated IL-1beta plasma levels. 2009Aksentijevich I， et al. Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population. 1999Cazeneuve C， et al. MEFV-Gene analysis in armenian patients with Familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications. 1999Sugiura T， et al. Familial Mediterranean fever in three Japanese patients， and a comparison of the frequency of MEFV gene mutations in Japanese and Mediterranean populations. 2007Ryan JG， et al. Clinical features and functional significance of the P369S/R408Q variant in pyrin， the familial Mediterranean fever protein. 2010Ulane RE， et al. A rapid accurate assay for choline kinase. 1977Oshima K， et al. A case of familial Mediterranean fever associated with compound heterozygosity for the pyrin variant L110P-E148Q/M680I in Japan. 2010Medlej-Hashim M， et al. 1Novel MEFV transcripts in Familial Mediterranean fever patients and controls. 2010Fil'shtinski? AIa， et al. [X-ray assessment of the motor-evacuatory function of the gastrointestinal tract in the diagnosis of the dumping-syndrome]. 1976Booth DR， et al. Pyrin/marenostrin mutations in familial Mediterranean fever. 1998Ben-Chetrit E， et al. The E148Q mutation in the MEFV gene: is it a disease-causing mutation or a sequence variant? 2000Cazeneuve C， et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. 2000Dodé C， et al. Mutational spectrum in the MEFV and TNFRSF1A genes in patients suffering from AA amyloidosis and recurrent inflammatory attacks. 2002Belmahi L， et al. Prevalence and distribution of MEFV mutations among Arabs from the Maghreb patients suffering from familial Mediterranean fever. 2006Nakano K， et al. Possible intervention of insulin， cyclic AMP， and glucocorticoids in protein-sparing action of dietary carbohydrate in rats. 1975Tchernitchko D， et al. Clinical evaluation of a reverse hybridization assay for the molecular detection of twelve MEFV gene mutations. 2003Sabbagh AS， et al. MEFV gene mutations spectrum among Lebanese patients referred for Familial Mediterranean Fever work-up: experience of a major tertiary care center. 2008Ben-Chetrit E， et al. Familial mediterranean Fever in the world. 2009	GENETIC_DISEASE			其他
家族性地中海热	常染色体隐性	MEFV	rs28940580	G/T	携带2个有害突变	Bernot A， et al. Non-founder mutations in the MEFV gene establish this gene as the cause of familial Mediterranean fever (FMF). 1998Villani AC， et al. Genetic variation in the familial Mediterranean fever gene (MEFV) and risk for Crohn's disease and ulcerative colitis. 2009Feng J， et al. Missense mutations in the MEFV gene are associated with fibromyalgia syndrome and correlate with elevated IL-1beta plasma levels. 2009Aksentijevich I， et al. Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population. 1999Cazeneuve C， et al. MEFV-Gene analysis in armenian patients with Familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications. 1999Sugiura T， et al. Familial Mediterranean fever in three Japanese patients， and a comparison of the frequency of MEFV gene mutations in Japanese and Mediterranean populations. 2007Ryan JG， et al. Clinical features and functional significance of the P369S/R408Q variant in pyrin， the familial Mediterranean fever protein. 2010Ulane RE， et al. A rapid accurate assay for choline kinase. 1977Oshima K， et al. A case of familial Mediterranean fever associated with compound heterozygosity for the pyrin variant L110P-E148Q/M680I in Japan. 2010Medlej-Hashim M， et al. 1Novel MEFV transcripts in Familial Mediterranean fever patients and controls. 2010Fil'shtinski? AIa， et al. [X-ray assessment of the motor-evacuatory function of the gastrointestinal tract in the diagnosis of the dumping-syndrome]. 1976Booth DR， et al. Pyrin/marenostrin mutations in familial Mediterranean fever. 1998Ben-Chetrit E， et al. The E148Q mutation in the MEFV gene: is it a disease-causing mutation or a sequence variant? 2000Cazeneuve C， et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. 2000Dodé C， et al. Mutational spectrum in the MEFV and TNFRSF1A genes in patients suffering from AA amyloidosis and recurrent inflammatory attacks. 2002Belmahi L， et al. Prevalence and distribution of MEFV mutations among Arabs from the Maghreb patients suffering from familial Mediterranean fever. 2006Nakano K， et al. Possible intervention of insulin， cyclic AMP， and glucocorticoids in protein-sparing action of dietary carbohydrate in rats. 1975Tchernitchko D， et al. Clinical evaluation of a reverse hybridization assay for the molecular detection of twelve MEFV gene mutations. 2003Sabbagh AS， et al. MEFV gene mutations spectrum among Lebanese patients referred for Familial Mediterranean Fever work-up: experience of a major tertiary care center. 2008Ben-Chetrit E， et al. Familial mediterranean Fever in the world. 2009	GENETIC_DISEASE			其他
家族性地中海热	常染色体隐性	MEFV	rs28940580	C/G	有害突变携带者	Bernot A， et al. Non-founder mutations in the MEFV gene establish this gene as the cause of familial Mediterranean fever (FMF). 1998Villani AC， et al. Genetic variation in the familial Mediterranean fever gene (MEFV) and risk for Crohn's disease and ulcerative colitis. 2009Feng J， et al. Missense mutations in the MEFV gene are associated with fibromyalgia syndrome and correlate with elevated IL-1beta plasma levels. 2009Aksentijevich I， et al. Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population. 1999Cazeneuve C， et al. MEFV-Gene analysis in armenian patients with Familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications. 1999Sugiura T， et al. Familial Mediterranean fever in three Japanese patients， and a comparison of the frequency of MEFV gene mutations in Japanese and Mediterranean populations. 2007Ryan JG， et al. Clinical features and functional significance of the P369S/R408Q variant in pyrin， the familial Mediterranean fever protein. 2010Ulane RE， et al. A rapid accurate assay for choline kinase. 1977Oshima K， et al. A case of familial Mediterranean fever associated with compound heterozygosity for the pyrin variant L110P-E148Q/M680I in Japan. 2010Medlej-Hashim M， et al. 1Novel MEFV transcripts in Familial Mediterranean fever patients and controls. 2010Fil'shtinski? AIa， et al. [X-ray assessment of the motor-evacuatory function of the gastrointestinal tract in the diagnosis of the dumping-syndrome]. 1976Booth DR， et al. Pyrin/marenostrin mutations in familial Mediterranean fever. 1998Ben-Chetrit E， et al. The E148Q mutation in the MEFV gene: is it a disease-causing mutation or a sequence variant? 2000Cazeneuve C， et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. 2000Dodé C， et al. Mutational spectrum in the MEFV and TNFRSF1A genes in patients suffering from AA amyloidosis and recurrent inflammatory attacks. 2002Belmahi L， et al. Prevalence and distribution of MEFV mutations among Arabs from the Maghreb patients suffering from familial Mediterranean fever. 2006Nakano K， et al. Possible intervention of insulin， cyclic AMP， and glucocorticoids in protein-sparing action of dietary carbohydrate in rats. 1975Tchernitchko D， et al. Clinical evaluation of a reverse hybridization assay for the molecular detection of twelve MEFV gene mutations. 2003Sabbagh AS， et al. MEFV gene mutations spectrum among Lebanese patients referred for Familial Mediterranean Fever work-up: experience of a major tertiary care center. 2008Ben-Chetrit E， et al. Familial mediterranean Fever in the world. 2009	GENETIC_DISEASE			其他
家族性地中海热	常染色体隐性	MEFV	rs28940580	C/T	有害突变携带者	Bernot A， et al. Non-founder mutations in the MEFV gene establish this gene as the cause of familial Mediterranean fever (FMF). 1998Villani AC， et al. Genetic variation in the familial Mediterranean fever gene (MEFV) and risk for Crohn's disease and ulcerative colitis. 2009Feng J， et al. Missense mutations in the MEFV gene are associated with fibromyalgia syndrome and correlate with elevated IL-1beta plasma levels. 2009Aksentijevich I， et al. Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population. 1999Cazeneuve C， et al. MEFV-Gene analysis in armenian patients with Familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications. 1999Sugiura T， et al. Familial Mediterranean fever in three Japanese patients， and a comparison of the frequency of MEFV gene mutations in Japanese and Mediterranean populations. 2007Ryan JG， et al. Clinical features and functional significance of the P369S/R408Q variant in pyrin， the familial Mediterranean fever protein. 2010Ulane RE， et al. A rapid accurate assay for choline kinase. 1977Oshima K， et al. A case of familial Mediterranean fever associated with compound heterozygosity for the pyrin variant L110P-E148Q/M680I in Japan. 2010Medlej-Hashim M， et al. 1Novel MEFV transcripts in Familial Mediterranean fever patients and controls. 2010Fil'shtinski? AIa， et al. [X-ray assessment of the motor-evacuatory function of the gastrointestinal tract in the diagnosis of the dumping-syndrome]. 1976Booth DR， et al. Pyrin/marenostrin mutations in familial Mediterranean fever. 1998Ben-Chetrit E， et al. The E148Q mutation in the MEFV gene: is it a disease-causing mutation or a sequence variant? 2000Cazeneuve C， et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. 2000Dodé C， et al. Mutational spectrum in the MEFV and TNFRSF1A genes in patients suffering from AA amyloidosis and recurrent inflammatory attacks. 2002Belmahi L， et al. Prevalence and distribution of MEFV mutations among Arabs from the Maghreb patients suffering from familial Mediterranean fever. 2006Nakano K， et al. Possible intervention of insulin， cyclic AMP， and glucocorticoids in protein-sparing action of dietary carbohydrate in rats. 1975Tchernitchko D， et al. Clinical evaluation of a reverse hybridization assay for the molecular detection of twelve MEFV gene mutations. 2003Sabbagh AS， et al. MEFV gene mutations spectrum among Lebanese patients referred for Familial Mediterranean Fever work-up: experience of a major tertiary care center. 2008Ben-Chetrit E， et al. Familial mediterranean Fever in the world. 2009	GENETIC_DISEASE			其他
家族性地中海热	常染色体隐性	MEFV	rs28940580	T/T	有害突变纯合	Bernot A， et al. Non-founder mutations in the MEFV gene establish this gene as the cause of familial Mediterranean fever (FMF). 1998Villani AC， et al. Genetic variation in the familial Mediterranean fever gene (MEFV) and risk for Crohn's disease and ulcerative colitis. 2009Feng J， et al. Missense mutations in the MEFV gene are associated with fibromyalgia syndrome and correlate with elevated IL-1beta plasma levels. 2009Aksentijevich I， et al. Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population. 1999Cazeneuve C， et al. MEFV-Gene analysis in armenian patients with Familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications. 1999Sugiura T， et al. Familial Mediterranean fever in three Japanese patients， and a comparison of the frequency of MEFV gene mutations in Japanese and Mediterranean populations. 2007Ryan JG， et al. Clinical features and functional significance of the P369S/R408Q variant in pyrin， the familial Mediterranean fever protein. 2010Ulane RE， et al. A rapid accurate assay for choline kinase. 1977Oshima K， et al. A case of familial Mediterranean fever associated with compound heterozygosity for the pyrin variant L110P-E148Q/M680I in Japan. 2010Medlej-Hashim M， et al. 1Novel MEFV transcripts in Familial Mediterranean fever patients and controls. 2010Fil'shtinski? AIa， et al. [X-ray assessment of the motor-evacuatory function of the gastrointestinal tract in the diagnosis of the dumping-syndrome]. 1976Booth DR， et al. Pyrin/marenostrin mutations in familial Mediterranean fever. 1998Ben-Chetrit E， et al. The E148Q mutation in the MEFV gene: is it a disease-causing mutation or a sequence variant? 2000Cazeneuve C， et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. 2000Dodé C， et al. Mutational spectrum in the MEFV and TNFRSF1A genes in patients suffering from AA amyloidosis and recurrent inflammatory attacks. 2002Belmahi L， et al. Prevalence and distribution of MEFV mutations among Arabs from the Maghreb patients suffering from familial Mediterranean fever. 2006Nakano K， et al. Possible intervention of insulin， cyclic AMP， and glucocorticoids in protein-sparing action of dietary carbohydrate in rats. 1975Tchernitchko D， et al. Clinical evaluation of a reverse hybridization assay for the molecular detection of twelve MEFV gene mutations. 2003Sabbagh AS， et al. MEFV gene mutations spectrum among Lebanese patients referred for Familial Mediterranean Fever work-up: experience of a major tertiary care center. 2008Ben-Chetrit E， et al. Familial mediterranean Fever in the world. 2009	GENETIC_DISEASE			其他
家族性地中海热	常染色体隐性	MEFV	rs28940577	T/T	正常基因型	Bernot A， et al. Non-founder mutations in the MEFV gene establish this gene as the cause of familial Mediterranean fever (FMF). 1998Villani AC， et al. Genetic variation in the familial Mediterranean fever gene (MEFV) and risk for Crohn's disease and ulcerative colitis. 2009Feng J， et al. Missense mutations in the MEFV gene are associated with fibromyalgia syndrome and correlate with elevated IL-1beta plasma levels. 2009Aksentijevich I， et al. Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population. 1999Cazeneuve C， et al. MEFV-Gene analysis in armenian patients with Familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications. 1999Sugiura T， et al. Familial Mediterranean fever in three Japanese patients， and a comparison of the frequency of MEFV gene mutations in Japanese and Mediterranean populations. 2007Ryan JG， et al. Clinical features and functional significance of the P369S/R408Q variant in pyrin， the familial Mediterranean fever protein. 2010Ulane RE， et al. A rapid accurate assay for choline kinase. 1977Oshima K， et al. A case of familial Mediterranean fever associated with compound heterozygosity for the pyrin variant L110P-E148Q/M680I in Japan. 2010Medlej-Hashim M， et al. 1Novel MEFV transcripts in Familial Mediterranean fever patients and controls. 2010Fil'shtinski? AIa， et al. [X-ray assessment of the motor-evacuatory function of the gastrointestinal tract in the diagnosis of the dumping-syndrome]. 1976Booth DR， et al. Pyrin/marenostrin mutations in familial Mediterranean fever. 1998Ben-Chetrit E， et al. The E148Q mutation in the MEFV gene: is it a disease-causing mutation or a sequence variant? 2000Cazeneuve C， et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. 2000Dodé C， et al. Mutational spectrum in the MEFV and TNFRSF1A genes in patients suffering from AA amyloidosis and recurrent inflammatory attacks. 2002Belmahi L， et al. Prevalence and distribution of MEFV mutations among Arabs from the Maghreb patients suffering from familial Mediterranean fever. 2006Nakano K， et al. Possible intervention of insulin， cyclic AMP， and glucocorticoids in protein-sparing action of dietary carbohydrate in rats. 1975Tchernitchko D， et al. Clinical evaluation of a reverse hybridization assay for the molecular detection of twelve MEFV gene mutations. 2003Sabbagh AS， et al. MEFV gene mutations spectrum among Lebanese patients referred for Familial Mediterranean Fever work-up: experience of a major tertiary care center. 2008Ben-Chetrit E， et al. Familial mediterranean Fever in the world. 2009	GENETIC_DISEASE			其他
家族性地中海热	常染色体隐性	MEFV	rs28940577	T/C	有害突变携带者	Bernot A， et al. Non-founder mutations in the MEFV gene establish this gene as the cause of familial Mediterranean fever (FMF). 1998Villani AC， et al. Genetic variation in the familial Mediterranean fever gene (MEFV) and risk for Crohn's disease and ulcerative colitis. 2009Feng J， et al. Missense mutations in the MEFV gene are associated with fibromyalgia syndrome and correlate with elevated IL-1beta plasma levels. 2009Aksentijevich I， et al. Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population. 1999Cazeneuve C， et al. MEFV-Gene analysis in armenian patients with Familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications. 1999Sugiura T， et al. Familial Mediterranean fever in three Japanese patients， and a comparison of the frequency of MEFV gene mutations in Japanese and Mediterranean populations. 2007Ryan JG， et al. Clinical features and functional significance of the P369S/R408Q variant in pyrin， the familial Mediterranean fever protein. 2010Ulane RE， et al. A rapid accurate assay for choline kinase. 1977Oshima K， et al. A case of familial Mediterranean fever associated with compound heterozygosity for the pyrin variant L110P-E148Q/M680I in Japan. 2010Medlej-Hashim M， et al. 1Novel MEFV transcripts in Familial Mediterranean fever patients and controls. 2010Fil'shtinski? AIa， et al. [X-ray assessment of the motor-evacuatory function of the gastrointestinal tract in the diagnosis of the dumping-syndrome]. 1976Booth DR， et al. Pyrin/marenostrin mutations in familial Mediterranean fever. 1998Ben-Chetrit E， et al. The E148Q mutation in the MEFV gene: is it a disease-causing mutation or a sequence variant? 2000Cazeneuve C， et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. 2000Dodé C， et al. Mutational spectrum in the MEFV and TNFRSF1A genes in patients suffering from AA amyloidosis and recurrent inflammatory attacks. 2002Belmahi L， et al. Prevalence and distribution of MEFV mutations among Arabs from the Maghreb patients suffering from familial Mediterranean fever. 2006Nakano K， et al. Possible intervention of insulin， cyclic AMP， and glucocorticoids in protein-sparing action of dietary carbohydrate in rats. 1975Tchernitchko D， et al. Clinical evaluation of a reverse hybridization assay for the molecular detection of twelve MEFV gene mutations. 2003Sabbagh AS， et al. MEFV gene mutations spectrum among Lebanese patients referred for Familial Mediterranean Fever work-up: experience of a major tertiary care center. 2008Ben-Chetrit E， et al. Familial mediterranean Fever in the world. 2009	GENETIC_DISEASE			其他
家族性地中海热	常染色体隐性	MEFV	rs28940577	C/C	有害突变纯合	Bernot A， et al. Non-founder mutations in the MEFV gene establish this gene as the cause of familial Mediterranean fever (FMF). 1998Villani AC， et al. Genetic variation in the familial Mediterranean fever gene (MEFV) and risk for Crohn's disease and ulcerative colitis. 2009Feng J， et al. Missense mutations in the MEFV gene are associated with fibromyalgia syndrome and correlate with elevated IL-1beta plasma levels. 2009Aksentijevich I， et al. Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population. 1999Cazeneuve C， et al. MEFV-Gene analysis in armenian patients with Familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications. 1999Sugiura T， et al. Familial Mediterranean fever in three Japanese patients， and a comparison of the frequency of MEFV gene mutations in Japanese and Mediterranean populations. 2007Ryan JG， et al. Clinical features and functional significance of the P369S/R408Q variant in pyrin， the familial Mediterranean fever protein. 2010Ulane RE， et al. A rapid accurate assay for choline kinase. 1977Oshima K， et al. A case of familial Mediterranean fever associated with compound heterozygosity for the pyrin variant L110P-E148Q/M680I in Japan. 2010Medlej-Hashim M， et al. 1Novel MEFV transcripts in Familial Mediterranean fever patients and controls. 2010Fil'shtinski? AIa， et al. [X-ray assessment of the motor-evacuatory function of the gastrointestinal tract in the diagnosis of the dumping-syndrome]. 1976Booth DR， et al. Pyrin/marenostrin mutations in familial Mediterranean fever. 1998Ben-Chetrit E， et al. The E148Q mutation in the MEFV gene: is it a disease-causing mutation or a sequence variant? 2000Cazeneuve C， et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. 2000Dodé C， et al. Mutational spectrum in the MEFV and TNFRSF1A genes in patients suffering from AA amyloidosis and recurrent inflammatory attacks. 2002Belmahi L， et al. Prevalence and distribution of MEFV mutations among Arabs from the Maghreb patients suffering from familial Mediterranean fever. 2006Nakano K， et al. Possible intervention of insulin， cyclic AMP， and glucocorticoids in protein-sparing action of dietary carbohydrate in rats. 1975Tchernitchko D， et al. Clinical evaluation of a reverse hybridization assay for the molecular detection of twelve MEFV gene mutations. 2003Sabbagh AS， et al. MEFV gene mutations spectrum among Lebanese patients referred for Familial Mediterranean Fever work-up: experience of a major tertiary care center. 2008Ben-Chetrit E， et al. Familial mediterranean Fever in the world. 2009	GENETIC_DISEASE			其他
家族性地中海热	常染色体隐性	MEFV	rs61752717	T/T	正常基因型	Bernot A， et al. Non-founder mutations in the MEFV gene establish this gene as the cause of familial Mediterranean fever (FMF). 1998Villani AC， et al. Genetic variation in the familial Mediterranean fever gene (MEFV) and risk for Crohn's disease and ulcerative colitis. 2009Feng J， et al. Missense mutations in the MEFV gene are associated with fibromyalgia syndrome and correlate with elevated IL-1beta plasma levels. 2009Aksentijevich I， et al. Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population. 1999Cazeneuve C， et al. MEFV-Gene analysis in armenian patients with Familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications. 1999Sugiura T， et al. Familial Mediterranean fever in three Japanese patients， and a comparison of the frequency of MEFV gene mutations in Japanese and Mediterranean populations. 2007Ryan JG， et al. Clinical features and functional significance of the P369S/R408Q variant in pyrin， the familial Mediterranean fever protein. 2010Ulane RE， et al. A rapid accurate assay for choline kinase. 1977Oshima K， et al. A case of familial Mediterranean fever associated with compound heterozygosity for the pyrin variant L110P-E148Q/M680I in Japan. 2010Medlej-Hashim M， et al. 1Novel MEFV transcripts in Familial Mediterranean fever patients and controls. 2010Fil'shtinski? AIa， et al. [X-ray assessment of the motor-evacuatory function of the gastrointestinal tract in the diagnosis of the dumping-syndrome]. 1976Booth DR， et al. Pyrin/marenostrin mutations in familial Mediterranean fever. 1998Ben-Chetrit E， et al. The E148Q mutation in the MEFV gene: is it a disease-causing mutation or a sequence variant? 2000Cazeneuve C， et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. 2000Dodé C， et al. Mutational spectrum in the MEFV and TNFRSF1A genes in patients suffering from AA amyloidosis and recurrent inflammatory attacks. 2002Belmahi L， et al. Prevalence and distribution of MEFV mutations among Arabs from the Maghreb patients suffering from familial Mediterranean fever. 2006Nakano K， et al. Possible intervention of insulin， cyclic AMP， and glucocorticoids in protein-sparing action of dietary carbohydrate in rats. 1975Tchernitchko D， et al. Clinical evaluation of a reverse hybridization assay for the molecular detection of twelve MEFV gene mutations. 2003Sabbagh AS， et al. MEFV gene mutations spectrum among Lebanese patients referred for Familial Mediterranean Fever work-up: experience of a major tertiary care center. 2008Ben-Chetrit E， et al. Familial mediterranean Fever in the world. 2009	GENETIC_DISEASE			其他
家族性地中海热	常染色体隐性	MEFV	rs61752717	T/C	有害突变携带者	Bernot A， et al. Non-founder mutations in the MEFV gene establish this gene as the cause of familial Mediterranean fever (FMF). 1998Villani AC， et al. Genetic variation in the familial Mediterranean fever gene (MEFV) and risk for Crohn's disease and ulcerative colitis. 2009Feng J， et al. Missense mutations in the MEFV gene are associated with fibromyalgia syndrome and correlate with elevated IL-1beta plasma levels. 2009Aksentijevich I， et al. Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population. 1999Cazeneuve C， et al. MEFV-Gene analysis in armenian patients with Familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications. 1999Sugiura T， et al. Familial Mediterranean fever in three Japanese patients， and a comparison of the frequency of MEFV gene mutations in Japanese and Mediterranean populations. 2007Ryan JG， et al. Clinical features and functional significance of the P369S/R408Q variant in pyrin， the familial Mediterranean fever protein. 2010Ulane RE， et al. A rapid accurate assay for choline kinase. 1977Oshima K， et al. A case of familial Mediterranean fever associated with compound heterozygosity for the pyrin variant L110P-E148Q/M680I in Japan. 2010Medlej-Hashim M， et al. 1Novel MEFV transcripts in Familial Mediterranean fever patients and controls. 2010Fil'shtinski? AIa， et al. [X-ray assessment of the motor-evacuatory function of the gastrointestinal tract in the diagnosis of the dumping-syndrome]. 1976Booth DR， et al. Pyrin/marenostrin mutations in familial Mediterranean fever. 1998Ben-Chetrit E， et al. The E148Q mutation in the MEFV gene: is it a disease-causing mutation or a sequence variant? 2000Cazeneuve C， et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. 2000Dodé C， et al. Mutational spectrum in the MEFV and TNFRSF1A genes in patients suffering from AA amyloidosis and recurrent inflammatory attacks. 2002Belmahi L， et al. Prevalence and distribution of MEFV mutations among Arabs from the Maghreb patients suffering from familial Mediterranean fever. 2006Nakano K， et al. Possible intervention of insulin， cyclic AMP， and glucocorticoids in protein-sparing action of dietary carbohydrate in rats. 1975Tchernitchko D， et al. Clinical evaluation of a reverse hybridization assay for the molecular detection of twelve MEFV gene mutations. 2003Sabbagh AS， et al. MEFV gene mutations spectrum among Lebanese patients referred for Familial Mediterranean Fever work-up: experience of a major tertiary care center. 2008Ben-Chetrit E， et al. Familial mediterranean Fever in the world. 2009	GENETIC_DISEASE			其他
家族性地中海热	常染色体隐性	MEFV	rs61752717	C/C	有害突变纯合	Bernot A， et al. Non-founder mutations in the MEFV gene establish this gene as the cause of familial Mediterranean fever (FMF). 1998Villani AC， et al. Genetic variation in the familial Mediterranean fever gene (MEFV) and risk for Crohn's disease and ulcerative colitis. 2009Feng J， et al. Missense mutations in the MEFV gene are associated with fibromyalgia syndrome and correlate with elevated IL-1beta plasma levels. 2009Aksentijevich I， et al. Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population. 1999Cazeneuve C， et al. MEFV-Gene analysis in armenian patients with Familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications. 1999Sugiura T， et al. Familial Mediterranean fever in three Japanese patients， and a comparison of the frequency of MEFV gene mutations in Japanese and Mediterranean populations. 2007Ryan JG， et al. Clinical features and functional significance of the P369S/R408Q variant in pyrin， the familial Mediterranean fever protein. 2010Ulane RE， et al. A rapid accurate assay for choline kinase. 1977Oshima K， et al. A case of familial Mediterranean fever associated with compound heterozygosity for the pyrin variant L110P-E148Q/M680I in Japan. 2010Medlej-Hashim M， et al. 1Novel MEFV transcripts in Familial Mediterranean fever patients and controls. 2010Fil'shtinski? AIa， et al. [X-ray assessment of the motor-evacuatory function of the gastrointestinal tract in the diagnosis of the dumping-syndrome]. 1976Booth DR， et al. Pyrin/marenostrin mutations in familial Mediterranean fever. 1998Ben-Chetrit E， et al. The E148Q mutation in the MEFV gene: is it a disease-causing mutation or a sequence variant? 2000Cazeneuve C， et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. 2000Dodé C， et al. Mutational spectrum in the MEFV and TNFRSF1A genes in patients suffering from AA amyloidosis and recurrent inflammatory attacks. 2002Belmahi L， et al. Prevalence and distribution of MEFV mutations among Arabs from the Maghreb patients suffering from familial Mediterranean fever. 2006Nakano K， et al. Possible intervention of insulin， cyclic AMP， and glucocorticoids in protein-sparing action of dietary carbohydrate in rats. 1975Tchernitchko D， et al. Clinical evaluation of a reverse hybridization assay for the molecular detection of twelve MEFV gene mutations. 2003Sabbagh AS， et al. MEFV gene mutations spectrum among Lebanese patients referred for Familial Mediterranean Fever work-up: experience of a major tertiary care center. 2008Ben-Chetrit E， et al. Familial mediterranean Fever in the world. 2009	GENETIC_DISEASE			其他
家族性地中海热	常染色体隐性	MEFV	rs61732874	C/C	正常基因型	Bernot A， et al. Non-founder mutations in the MEFV gene establish this gene as the cause of familial Mediterranean fever (FMF). 1998Villani AC， et al. Genetic variation in the familial Mediterranean fever gene (MEFV) and risk for Crohn's disease and ulcerative colitis. 2009Feng J， et al. Missense mutations in the MEFV gene are associated with fibromyalgia syndrome and correlate with elevated IL-1beta plasma levels. 2009Aksentijevich I， et al. Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population. 1999Cazeneuve C， et al. MEFV-Gene analysis in armenian patients with Familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications. 1999Sugiura T， et al. Familial Mediterranean fever in three Japanese patients， and a comparison of the frequency of MEFV gene mutations in Japanese and Mediterranean populations. 2007Ryan JG， et al. Clinical features and functional significance of the P369S/R408Q variant in pyrin， the familial Mediterranean fever protein. 2010Ulane RE， et al. A rapid accurate assay for choline kinase. 1977Oshima K， et al. A case of familial Mediterranean fever associated with compound heterozygosity for the pyrin variant L110P-E148Q/M680I in Japan. 2010Medlej-Hashim M， et al. 1Novel MEFV transcripts in Familial Mediterranean fever patients and controls. 2010Fil'shtinski? AIa， et al. [X-ray assessment of the motor-evacuatory function of the gastrointestinal tract in the diagnosis of the dumping-syndrome]. 1976Booth DR， et al. Pyrin/marenostrin mutations in familial Mediterranean fever. 1998Ben-Chetrit E， et al. The E148Q mutation in the MEFV gene: is it a disease-causing mutation or a sequence variant? 2000Cazeneuve C， et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. 2000Dodé C， et al. Mutational spectrum in the MEFV and TNFRSF1A genes in patients suffering from AA amyloidosis and recurrent inflammatory attacks. 2002Belmahi L， et al. Prevalence and distribution of MEFV mutations among Arabs from the Maghreb patients suffering from familial Mediterranean fever. 2006Nakano K， et al. Possible intervention of insulin， cyclic AMP， and glucocorticoids in protein-sparing action of dietary carbohydrate in rats. 1975Tchernitchko D， et al. Clinical evaluation of a reverse hybridization assay for the molecular detection of twelve MEFV gene mutations. 2003Sabbagh AS， et al. MEFV gene mutations spectrum among Lebanese patients referred for Familial Mediterranean Fever work-up: experience of a major tertiary care center. 2008Ben-Chetrit E， et al. Familial mediterranean Fever in the world. 2009	GENETIC_DISEASE			其他
家族性地中海热	常染色体隐性	MEFV	rs61732874	C/A	有害突变携带者	Bernot A， et al. Non-founder mutations in the MEFV gene establish this gene as the cause of familial Mediterranean fever (FMF). 1998Villani AC， et al. Genetic variation in the familial Mediterranean fever gene (MEFV) and risk for Crohn's disease and ulcerative colitis. 2009Feng J， et al. Missense mutations in the MEFV gene are associated with fibromyalgia syndrome and correlate with elevated IL-1beta plasma levels. 2009Aksentijevich I， et al. Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population. 1999Cazeneuve C， et al. MEFV-Gene analysis in armenian patients with Familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications. 1999Sugiura T， et al. Familial Mediterranean fever in three Japanese patients， and a comparison of the frequency of MEFV gene mutations in Japanese and Mediterranean populations. 2007Ryan JG， et al. Clinical features and functional significance of the P369S/R408Q variant in pyrin， the familial Mediterranean fever protein. 2010Ulane RE， et al. A rapid accurate assay for choline kinase. 1977Oshima K， et al. A case of familial Mediterranean fever associated with compound heterozygosity for the pyrin variant L110P-E148Q/M680I in Japan. 2010Medlej-Hashim M， et al. 1Novel MEFV transcripts in Familial Mediterranean fever patients and controls. 2010Fil'shtinski? AIa， et al. [X-ray assessment of the motor-evacuatory function of the gastrointestinal tract in the diagnosis of the dumping-syndrome]. 1976Booth DR， et al. Pyrin/marenostrin mutations in familial Mediterranean fever. 1998Ben-Chetrit E， et al. The E148Q mutation in the MEFV gene: is it a disease-causing mutation or a sequence variant? 2000Cazeneuve C， et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. 2000Dodé C， et al. Mutational spectrum in the MEFV and TNFRSF1A genes in patients suffering from AA amyloidosis and recurrent inflammatory attacks. 2002Belmahi L， et al. Prevalence and distribution of MEFV mutations among Arabs from the Maghreb patients suffering from familial Mediterranean fever. 2006Nakano K， et al. Possible intervention of insulin， cyclic AMP， and glucocorticoids in protein-sparing action of dietary carbohydrate in rats. 1975Tchernitchko D， et al. Clinical evaluation of a reverse hybridization assay for the molecular detection of twelve MEFV gene mutations. 2003Sabbagh AS， et al. MEFV gene mutations spectrum among Lebanese patients referred for Familial Mediterranean Fever work-up: experience of a major tertiary care center. 2008Ben-Chetrit E， et al. Familial mediterranean Fever in the world. 2009	GENETIC_DISEASE			其他
家族性地中海热	常染色体隐性	MEFV	rs61732874	A/A	有害突变纯合	Bernot A， et al. Non-founder mutations in the MEFV gene establish this gene as the cause of familial Mediterranean fever (FMF). 1998Villani AC， et al. Genetic variation in the familial Mediterranean fever gene (MEFV) and risk for Crohn's disease and ulcerative colitis. 2009Feng J， et al. Missense mutations in the MEFV gene are associated with fibromyalgia syndrome and correlate with elevated IL-1beta plasma levels. 2009Aksentijevich I， et al. Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population. 1999Cazeneuve C， et al. MEFV-Gene analysis in armenian patients with Familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications. 1999Sugiura T， et al. Familial Mediterranean fever in three Japanese patients， and a comparison of the frequency of MEFV gene mutations in Japanese and Mediterranean populations. 2007Ryan JG， et al. Clinical features and functional significance of the P369S/R408Q variant in pyrin， the familial Mediterranean fever protein. 2010Ulane RE， et al. A rapid accurate assay for choline kinase. 1977Oshima K， et al. A case of familial Mediterranean fever associated with compound heterozygosity for the pyrin variant L110P-E148Q/M680I in Japan. 2010Medlej-Hashim M， et al. 1Novel MEFV transcripts in Familial Mediterranean fever patients and controls. 2010Fil'shtinski? AIa， et al. [X-ray assessment of the motor-evacuatory function of the gastrointestinal tract in the diagnosis of the dumping-syndrome]. 1976Booth DR， et al. Pyrin/marenostrin mutations in familial Mediterranean fever. 1998Ben-Chetrit E， et al. The E148Q mutation in the MEFV gene: is it a disease-causing mutation or a sequence variant? 2000Cazeneuve C， et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. 2000Dodé C， et al. Mutational spectrum in the MEFV and TNFRSF1A genes in patients suffering from AA amyloidosis and recurrent inflammatory attacks. 2002Belmahi L， et al. Prevalence and distribution of MEFV mutations among Arabs from the Maghreb patients suffering from familial Mediterranean fever. 2006Nakano K， et al. Possible intervention of insulin， cyclic AMP， and glucocorticoids in protein-sparing action of dietary carbohydrate in rats. 1975Tchernitchko D， et al. Clinical evaluation of a reverse hybridization assay for the molecular detection of twelve MEFV gene mutations. 2003Sabbagh AS， et al. MEFV gene mutations spectrum among Lebanese patients referred for Familial Mediterranean Fever work-up: experience of a major tertiary care center. 2008Ben-Chetrit E， et al. Familial mediterranean Fever in the world. 2009	GENETIC_DISEASE			其他
家族性地中海热	常染色体隐性	MEFV	rs104895094	T/T	正常基因型	Bernot A， et al. Non-founder mutations in the MEFV gene establish this gene as the cause of familial Mediterranean fever (FMF). 1998Villani AC， et al. Genetic variation in the familial Mediterranean fever gene (MEFV) and risk for Crohn's disease and ulcerative colitis. 2009Feng J， et al. Missense mutations in the MEFV gene are associated with fibromyalgia syndrome and correlate with elevated IL-1beta plasma levels. 2009Aksentijevich I， et al. Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population. 1999Cazeneuve C， et al. MEFV-Gene analysis in armenian patients with Familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications. 1999Sugiura T， et al. Familial Mediterranean fever in three Japanese patients， and a comparison of the frequency of MEFV gene mutations in Japanese and Mediterranean populations. 2007Ryan JG， et al. Clinical features and functional significance of the P369S/R408Q variant in pyrin， the familial Mediterranean fever protein. 2010Ulane RE， et al. A rapid accurate assay for choline kinase. 1977Oshima K， et al. A case of familial Mediterranean fever associated with compound heterozygosity for the pyrin variant L110P-E148Q/M680I in Japan. 2010Medlej-Hashim M， et al. 1Novel MEFV transcripts in Familial Mediterranean fever patients and controls. 2010Fil'shtinski? AIa， et al. [X-ray assessment of the motor-evacuatory function of the gastrointestinal tract in the diagnosis of the dumping-syndrome]. 1976Booth DR， et al. Pyrin/marenostrin mutations in familial Mediterranean fever. 1998Ben-Chetrit E， et al. The E148Q mutation in the MEFV gene: is it a disease-causing mutation or a sequence variant? 2000Cazeneuve C， et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. 2000Dodé C， et al. Mutational spectrum in the MEFV and TNFRSF1A genes in patients suffering from AA amyloidosis and recurrent inflammatory attacks. 2002Belmahi L， et al. Prevalence and distribution of MEFV mutations among Arabs from the Maghreb patients suffering from familial Mediterranean fever. 2006Nakano K， et al. Possible intervention of insulin， cyclic AMP， and glucocorticoids in protein-sparing action of dietary carbohydrate in rats. 1975Tchernitchko D， et al. Clinical evaluation of a reverse hybridization assay for the molecular detection of twelve MEFV gene mutations. 2003Sabbagh AS， et al. MEFV gene mutations spectrum among Lebanese patients referred for Familial Mediterranean Fever work-up: experience of a major tertiary care center. 2008Ben-Chetrit E， et al. Familial mediterranean Fever in the world. 2009	GENETIC_DISEASE			其他
家族性地中海热	常染色体隐性	MEFV	rs104895094	T/C	有害突变携带者	Bernot A， et al. Non-founder mutations in the MEFV gene establish this gene as the cause of familial Mediterranean fever (FMF). 1998Villani AC， et al. Genetic variation in the familial Mediterranean fever gene (MEFV) and risk for Crohn's disease and ulcerative colitis. 2009Feng J， et al. Missense mutations in the MEFV gene are associated with fibromyalgia syndrome and correlate with elevated IL-1beta plasma levels. 2009Aksentijevich I， et al. Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population. 1999Cazeneuve C， et al. MEFV-Gene analysis in armenian patients with Familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications. 1999Sugiura T， et al. Familial Mediterranean fever in three Japanese patients， and a comparison of the frequency of MEFV gene mutations in Japanese and Mediterranean populations. 2007Ryan JG， et al. Clinical features and functional significance of the P369S/R408Q variant in pyrin， the familial Mediterranean fever protein. 2010Ulane RE， et al. A rapid accurate assay for choline kinase. 1977Oshima K， et al. A case of familial Mediterranean fever associated with compound heterozygosity for the pyrin variant L110P-E148Q/M680I in Japan. 2010Medlej-Hashim M， et al. 1Novel MEFV transcripts in Familial Mediterranean fever patients and controls. 2010Fil'shtinski? AIa， et al. [X-ray assessment of the motor-evacuatory function of the gastrointestinal tract in the diagnosis of the dumping-syndrome]. 1976Booth DR， et al. Pyrin/marenostrin mutations in familial Mediterranean fever. 1998Ben-Chetrit E， et al. The E148Q mutation in the MEFV gene: is it a disease-causing mutation or a sequence variant? 2000Cazeneuve C， et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. 2000Dodé C， et al. Mutational spectrum in the MEFV and TNFRSF1A genes in patients suffering from AA amyloidosis and recurrent inflammatory attacks. 2002Belmahi L， et al. Prevalence and distribution of MEFV mutations among Arabs from the Maghreb patients suffering from familial Mediterranean fever. 2006Nakano K， et al. Possible intervention of insulin， cyclic AMP， and glucocorticoids in protein-sparing action of dietary carbohydrate in rats. 1975Tchernitchko D， et al. Clinical evaluation of a reverse hybridization assay for the molecular detection of twelve MEFV gene mutations. 2003Sabbagh AS， et al. MEFV gene mutations spectrum among Lebanese patients referred for Familial Mediterranean Fever work-up: experience of a major tertiary care center. 2008Ben-Chetrit E， et al. Familial mediterranean Fever in the world. 2009	GENETIC_DISEASE			其他
家族性地中海热	常染色体隐性	MEFV	rs104895094	C/C	有害突变纯合	Bernot A， et al. Non-founder mutations in the MEFV gene establish this gene as the cause of familial Mediterranean fever (FMF). 1998Villani AC， et al. Genetic variation in the familial Mediterranean fever gene (MEFV) and risk for Crohn's disease and ulcerative colitis. 2009Feng J， et al. Missense mutations in the MEFV gene are associated with fibromyalgia syndrome and correlate with elevated IL-1beta plasma levels. 2009Aksentijevich I， et al. Mutation and haplotype studies of familial Mediterranean fever reveal new ancestral relationships and evidence for a high carrier frequency with reduced penetrance in the Ashkenazi Jewish population. 1999Cazeneuve C， et al. MEFV-Gene analysis in armenian patients with Familial Mediterranean fever: diagnostic value and unfavorable renal prognosis of the M694V homozygous genotype-genetic and therapeutic implications. 1999Sugiura T， et al. Familial Mediterranean fever in three Japanese patients， and a comparison of the frequency of MEFV gene mutations in Japanese and Mediterranean populations. 2007Ryan JG， et al. Clinical features and functional significance of the P369S/R408Q variant in pyrin， the familial Mediterranean fever protein. 2010Ulane RE， et al. A rapid accurate assay for choline kinase. 1977Oshima K， et al. A case of familial Mediterranean fever associated with compound heterozygosity for the pyrin variant L110P-E148Q/M680I in Japan. 2010Medlej-Hashim M， et al. 1Novel MEFV transcripts in Familial Mediterranean fever patients and controls. 2010Fil'shtinski? AIa， et al. [X-ray assessment of the motor-evacuatory function of the gastrointestinal tract in the diagnosis of the dumping-syndrome]. 1976Booth DR， et al. Pyrin/marenostrin mutations in familial Mediterranean fever. 1998Ben-Chetrit E， et al. The E148Q mutation in the MEFV gene: is it a disease-causing mutation or a sequence variant? 2000Cazeneuve C， et al. Identification of MEFV-independent modifying genetic factors for familial Mediterranean fever. 2000Dodé C， et al. Mutational spectrum in the MEFV and TNFRSF1A genes in patients suffering from AA amyloidosis and recurrent inflammatory attacks. 2002Belmahi L， et al. Prevalence and distribution of MEFV mutations among Arabs from the Maghreb patients suffering from familial Mediterranean fever. 2006Nakano K， et al. Possible intervention of insulin， cyclic AMP， and glucocorticoids in protein-sparing action of dietary carbohydrate in rats. 1975Tchernitchko D， et al. Clinical evaluation of a reverse hybridization assay for the molecular detection of twelve MEFV gene mutations. 2003Sabbagh AS， et al. MEFV gene mutations spectrum among Lebanese patients referred for Familial Mediterranean Fever work-up: experience of a major tertiary care center. 2008Ben-Chetrit E， et al. Familial mediterranean Fever in the world. 2009	GENETIC_DISEASE			其他
IV型粘脂贮积症	常染色体隐性	MCOLN1	rs104886461	A/A	正常基因型		GENETIC_DISEASE			遗传代谢
IV型粘脂贮积症	常染色体隐性	MCOLN1	rs104886461	A/G	有害突变携带者		GENETIC_DISEASE			遗传代谢
IV型粘脂贮积症	常染色体隐性	MCOLN1	rs104886461	G/G	有害突变纯合		GENETIC_DISEASE			遗传代谢
卡纳万病	常染色体隐性	ASPA	rs28940279	A/A	正常基因型	Matalon R， et al. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. 1988Kaul R， et al. Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease. 1993Elpeleg ON， et al. The frequency of the C854 mutation in the aspartoacylase gene in Ashkenazi Jews in Israel. 1994BANKER BQ， et al. SPONGY DEGENERATION OF THE CENTRAL NERVOUS SYSTEM IN INFANCY. 1964	GENETIC_DISEASE			神经系统
卡纳万病	常染色体隐性	ASPA	rs28940279	A/C	有害突变携带者	Matalon R， et al. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. 1988Kaul R， et al. Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease. 1993Elpeleg ON， et al. The frequency of the C854 mutation in the aspartoacylase gene in Ashkenazi Jews in Israel. 1994BANKER BQ， et al. SPONGY DEGENERATION OF THE CENTRAL NERVOUS SYSTEM IN INFANCY. 1964	GENETIC_DISEASE			神经系统
卡纳万病	常染色体隐性	ASPA	rs28940279	C/C	有害突变纯合	Matalon R， et al. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. 1988Kaul R， et al. Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease. 1993Elpeleg ON， et al. The frequency of the C854 mutation in the aspartoacylase gene in Ashkenazi Jews in Israel. 1994BANKER BQ， et al. SPONGY DEGENERATION OF THE CENTRAL NERVOUS SYSTEM IN INFANCY. 1964	GENETIC_DISEASE			神经系统
卡纳万病	常染色体隐性	ASPA	rs28940574	C/C	正常基因型	Matalon R， et al. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. 1988Kaul R， et al. Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease. 1993Elpeleg ON， et al. The frequency of the C854 mutation in the aspartoacylase gene in Ashkenazi Jews in Israel. 1994BANKER BQ， et al. SPONGY DEGENERATION OF THE CENTRAL NERVOUS SYSTEM IN INFANCY. 1964	GENETIC_DISEASE			神经系统
卡纳万病	常染色体隐性	ASPA	rs28940574	C/A	有害突变携带者	Matalon R， et al. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. 1988Kaul R， et al. Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease. 1993Elpeleg ON， et al. The frequency of the C854 mutation in the aspartoacylase gene in Ashkenazi Jews in Israel. 1994BANKER BQ， et al. SPONGY DEGENERATION OF THE CENTRAL NERVOUS SYSTEM IN INFANCY. 1964	GENETIC_DISEASE			神经系统
卡纳万病	常染色体隐性	ASPA	rs28940574	A/A	有害突变纯合	Matalon R， et al. Aspartoacylase deficiency and N-acetylaspartic aciduria in patients with Canavan disease. 1988Kaul R， et al. Cloning of the human aspartoacylase cDNA and a common missense mutation in Canavan disease. 1993Elpeleg ON， et al. The frequency of the C854 mutation in the aspartoacylase gene in Ashkenazi Jews in Israel. 1994BANKER BQ， et al. SPONGY DEGENERATION OF THE CENTRAL NERVOUS SYSTEM IN INFANCY. 1964	GENETIC_DISEASE			神经系统
肌张力障碍	常染色体显性	TOR1A	rs80358233	CTC/CTC	正常基因型	Narayanan R， et al. The response of a prostaglandin synthase preparation to the concentration of arachidonic acid [proceedings]. 1979Ozelius LJ， et al. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. 1997Grundmann K， et al. Frequency and phenotypic variability of the GAG deletion of the DYT1 gene in an unselected group of patients with dystonia. 2003Goodchild RE， et al. Mislocalization to the nuclear envelope: an effect of the dystonia-causing torsinA mutation. 2004Goodchild RE， et al. Loss of the dystonia-associated protein torsinA selectively disrupts the neuronal nuclear envelope. 2005Greene PE， et al. Stiff child syndrome with mutation of DYT1 gene. 2006	GENETIC_DISEASE			神经系统
肌张力障碍	常染色体显性	TOR1A	rs80358233	CTC/-	有害突变携带者	Narayanan R， et al. The response of a prostaglandin synthase preparation to the concentration of arachidonic acid [proceedings]. 1979Ozelius LJ， et al. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. 1997Grundmann K， et al. Frequency and phenotypic variability of the GAG deletion of the DYT1 gene in an unselected group of patients with dystonia. 2003Goodchild RE， et al. Mislocalization to the nuclear envelope: an effect of the dystonia-causing torsinA mutation. 2004Goodchild RE， et al. Loss of the dystonia-associated protein torsinA selectively disrupts the neuronal nuclear envelope. 2005Greene PE， et al. Stiff child syndrome with mutation of DYT1 gene. 2006	GENETIC_DISEASE			神经系统
肌张力障碍	常染色体显性	TOR1A	rs80358233	-/-	有害突变纯合	Narayanan R， et al. The response of a prostaglandin synthase preparation to the concentration of arachidonic acid [proceedings]. 1979Ozelius LJ， et al. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. 1997Grundmann K， et al. Frequency and phenotypic variability of the GAG deletion of the DYT1 gene in an unselected group of patients with dystonia. 2003Goodchild RE， et al. Mislocalization to the nuclear envelope: an effect of the dystonia-causing torsinA mutation. 2004Goodchild RE， et al. Loss of the dystonia-associated protein torsinA selectively disrupts the neuronal nuclear envelope. 2005Greene PE， et al. Stiff child syndrome with mutation of DYT1 gene. 2006	GENETIC_DISEASE			神经系统
先天性1A型糖基化病	常染色体隐性	PMM2	rs28936415	G/G	正常基因型	Matthijs G， et al. Mutations in PMM2， a phosphomannomutase gene on chromosome 16p13， in carbohydrate-deficient glycoprotein type I syndrome (Jaeken syndrome). 1997Kjaergaard S， et al. Absence of homozygosity for predominant mutations in PMM2 in Danish patients with carbohydrate-deficient glycoprotein syndrome type 1. 1998	GENETIC_DISEASE			其他
先天性1A型糖基化病	常染色体隐性	PMM2	rs28936415	G/A	有害突变携带者	Matthijs G， et al. Mutations in PMM2， a phosphomannomutase gene on chromosome 16p13， in carbohydrate-deficient glycoprotein type I syndrome (Jaeken syndrome). 1997Kjaergaard S， et al. Absence of homozygosity for predominant mutations in PMM2 in Danish patients with carbohydrate-deficient glycoprotein syndrome type 1. 1998	GENETIC_DISEASE			其他
先天性1A型糖基化病	常染色体隐性	PMM2	rs28936415	A/A	有害突变纯合	Matthijs G， et al. Mutations in PMM2， a phosphomannomutase gene on chromosome 16p13， in carbohydrate-deficient glycoprotein type I syndrome (Jaeken syndrome). 1997Kjaergaard S， et al. Absence of homozygosity for predominant mutations in PMM2 in Danish patients with carbohydrate-deficient glycoprotein syndrome type 1. 1998	GENETIC_DISEASE			其他
遗传性耳聋		GJB2	rs80338939	C/C	正常基因型	David TJ， et al. Trisomy 21 and trisomy 18 in half-siblings. 2015Carrasquillo MM， et al. Two different connexin 26 mutations in an inbred kindred segregating non-syndromic recessive deafness: implications for genetic studies in isolated populations. 1997Abe S， et al. Prevalent connexin 26 gene (GJB2) mutations in Japanese. 2000Anichkina A， et al. On the origin and frequency of the 35delG allele in GJB2-linked deafness in Europe. 2001D'Andrea P， et al. Hearing loss: frequency and functional studies of the most common connexin26 alleles. 2002Alvarez A， et al. High prevalence of the W24X mutation in the gene encoding connexin-26 (GJB2) in Spanish Romani (gypsies) with autosomal recessive non-syndromic hearing loss. 2005Morell RJ， et al. Mutations in the connexin 26 gene (GJB2) among Ashkenazi Jews with nonsyndromic recessive deafness. 1998Sobe T， et al. High frequency of the deafness-associated 167delT mutation in the connexin 26 (GJB2) gene in Israeli Ashkenazim. 1999Sobe T， et al. The prevalence and expression of inherited connexin 26 mutations associated with nonsyndromic hearing loss in the Israeli population. 2000Dong J， et al. Nonradioactive detection of the common Connexin 26 167delT and 35delG mutations and frequencies among Ashkenazi Jews. 2001Lerer I， et al. A deletion mutation in GJB6 cooperating with a GJB2 mutation in trans in non-syndromic deafness: A novel founder mutation in Ashkenazi Jews. 2001	GENETIC_DISEASE			耳鼻喉
遗传性耳聋		GJB2	rs80338939	C/-	有害突变携带者	David TJ， et al. Trisomy 21 and trisomy 18 in half-siblings. 2015Carrasquillo MM， et al. Two different connexin 26 mutations in an inbred kindred segregating non-syndromic recessive deafness: implications for genetic studies in isolated populations. 1997Abe S， et al. Prevalent connexin 26 gene (GJB2) mutations in Japanese. 2000Anichkina A， et al. On the origin and frequency of the 35delG allele in GJB2-linked deafness in Europe. 2001D'Andrea P， et al. Hearing loss: frequency and functional studies of the most common connexin26 alleles. 2002Alvarez A， et al. High prevalence of the W24X mutation in the gene encoding connexin-26 (GJB2) in Spanish Romani (gypsies) with autosomal recessive non-syndromic hearing loss. 2005Morell RJ， et al. Mutations in the connexin 26 gene (GJB2) among Ashkenazi Jews with nonsyndromic recessive deafness. 1998Sobe T， et al. High frequency of the deafness-associated 167delT mutation in the connexin 26 (GJB2) gene in Israeli Ashkenazim. 1999Sobe T， et al. The prevalence and expression of inherited connexin 26 mutations associated with nonsyndromic hearing loss in the Israeli population. 2000Dong J， et al. Nonradioactive detection of the common Connexin 26 167delT and 35delG mutations and frequencies among Ashkenazi Jews. 2001Lerer I， et al. A deletion mutation in GJB6 cooperating with a GJB2 mutation in trans in non-syndromic deafness: A novel founder mutation in Ashkenazi Jews. 2001	GENETIC_DISEASE			耳鼻喉
遗传性耳聋		GJB2	rs80338939	-/-	有害突变纯合	David TJ， et al. Trisomy 21 and trisomy 18 in half-siblings. 2015Carrasquillo MM， et al. Two different connexin 26 mutations in an inbred kindred segregating non-syndromic recessive deafness: implications for genetic studies in isolated populations. 1997Abe S， et al. Prevalent connexin 26 gene (GJB2) mutations in Japanese. 2000Anichkina A， et al. On the origin and frequency of the 35delG allele in GJB2-linked deafness in Europe. 2001D'Andrea P， et al. Hearing loss: frequency and functional studies of the most common connexin26 alleles. 2002Alvarez A， et al. High prevalence of the W24X mutation in the gene encoding connexin-26 (GJB2) in Spanish Romani (gypsies) with autosomal recessive non-syndromic hearing loss. 2005Morell RJ， et al. Mutations in the connexin 26 gene (GJB2) among Ashkenazi Jews with nonsyndromic recessive deafness. 1998Sobe T， et al. High frequency of the deafness-associated 167delT mutation in the connexin 26 (GJB2) gene in Israeli Ashkenazim. 1999Sobe T， et al. The prevalence and expression of inherited connexin 26 mutations associated with nonsyndromic hearing loss in the Israeli population. 2000Dong J， et al. Nonradioactive detection of the common Connexin 26 167delT and 35delG mutations and frequencies among Ashkenazi Jews. 2001Lerer I， et al. A deletion mutation in GJB6 cooperating with a GJB2 mutation in trans in non-syndromic deafness: A novel founder mutation in Ashkenazi Jews. 2001	GENETIC_DISEASE			耳鼻喉
唾液酸沉积症	常染色体隐性	SLC17A5	rs80338794	G/G	正常基因型	Verheijen FW， et al. A new gene， encoding an anion transporter， is mutated in sialic acid storage diseases. 1999Aula N， et al. The spectrum of SLC17A5-gene mutations resulting in free sialic acid-storage diseases indicates some genotype-phenotype correlation. 2000Varho TT， et al. Phenotypic spectrum of Salla disease， a free sialic acid storage disorder. 2002Kleta R， et al. Biochemical and molecular analyses of infantile free sialic acid storage disease in North American children. 2003Biancheri R， et al. Homozygosity for the p.K136E mutation in the SLC17A5 gene as cause of an Italian severe Salla disease. 2005	GENETIC_DISEASE			遗传代谢
唾液酸沉积症	常染色体隐性	SLC17A5	rs80338794	G/A	有害突变携带者	Verheijen FW， et al. A new gene， encoding an anion transporter， is mutated in sialic acid storage diseases. 1999Aula N， et al. The spectrum of SLC17A5-gene mutations resulting in free sialic acid-storage diseases indicates some genotype-phenotype correlation. 2000Varho TT， et al. Phenotypic spectrum of Salla disease， a free sialic acid storage disorder. 2002Kleta R， et al. Biochemical and molecular analyses of infantile free sialic acid storage disease in North American children. 2003Biancheri R， et al. Homozygosity for the p.K136E mutation in the SLC17A5 gene as cause of an Italian severe Salla disease. 2005	GENETIC_DISEASE			遗传代谢
唾液酸沉积症	常染色体隐性	SLC17A5	rs80338794	A/A	有害突变纯合	Verheijen FW， et al. A new gene， encoding an anion transporter， is mutated in sialic acid storage diseases. 1999Aula N， et al. The spectrum of SLC17A5-gene mutations resulting in free sialic acid-storage diseases indicates some genotype-phenotype correlation. 2000Varho TT， et al. Phenotypic spectrum of Salla disease， a free sialic acid storage disorder. 2002Kleta R， et al. Biochemical and molecular analyses of infantile free sialic acid storage disease in North American children. 2003Biancheri R， et al. Homozygosity for the p.K136E mutation in the SLC17A5 gene as cause of an Italian severe Salla disease. 2005	GENETIC_DISEASE			遗传代谢
血色素沉着病	常染色体隐性	HFE	rs1800730	A/A	正常基因型	Crownover BK， et al. Hereditary hemochromatosis. 2013Mura C， et al. HFE mutations analysis in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis. 1999Lian J， et al. Meta-analyses of HFE variants in coronary heart disease. 2013	GENETIC_DISEASE			遗传代谢
血色素沉着病	常染色体隐性	HFE	rs1800730	A/T	有害突变携带者	Crownover BK， et al. Hereditary hemochromatosis. 2013Mura C， et al. HFE mutations analysis in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis. 1999Lian J， et al. Meta-analyses of HFE variants in coronary heart disease. 2013	GENETIC_DISEASE			遗传代谢
血色素沉着病	常染色体隐性	HFE	rs1800730	T/T	有害突变纯合	Crownover BK， et al. Hereditary hemochromatosis. 2013Mura C， et al. HFE mutations analysis in 711 hemochromatosis probands: evidence for S65C implication in mild form of hemochromatosis. 1999Lian J， et al. Meta-analyses of HFE variants in coronary heart disease. 2013	GENETIC_DISEASE			遗传代谢
囊性纤维化	常染色体隐性	CFTR	rs77010898	G/G	正常基因型	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs77010898	G/A	有害突变携带者	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs77010898	A/A	有害突变纯合	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs78756941	G/G	正常基因型	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs78756941	G/T	有害突变携带者	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs78756941	T/T	有害突变纯合	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs80224560	G/G	正常基因型	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs80224560	G/A	有害突变携带者	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs80224560	A/A	有害突变纯合	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs80055610	G/G	正常基因型	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs80055610	G/A	有害突变携带者	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs80055610	A/A	有害突变纯合	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs80055610	C/C	有害突变纯合	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs80055610	G/C	有害突变携带者	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs78655421	G/G	正常基因型	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs78655421	G/A	有害突变携带者	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs78655421	A/A	有害突变纯合	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs77932196	G/G	正常基因型	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs77932196	G/C	有害突变携带者	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs77932196	G/A	有害突变携带者	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs77932196	A/A	有害突变纯合	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs77932196	C/C	有害突变纯合	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs77834169	C/C	正常基因型	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs77834169	C/T	有害突变携带者	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs77834169	T/T	有害突变纯合	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs77646904	G/G	正常基因型	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs77646904	G/A	有害突变携带者	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs77646904	A/A	有害突变纯合	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs75961395	G/G	正常基因型	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs75961395	G/A	有害突变携带者	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs75961395	A/A	有害突变纯合	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs75039782	C/C	正常基因型	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs75039782	C/T	有害突变携带者	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs75039782	T/T	有害突变纯合	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs74597325	C/C	正常基因型	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs74597325	C/T	有害突变携带者	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs74597325	T/T	有害突变纯合	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs113993960	TCT/TCT	正常基因型	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs113993960	-/TCT	有害突变携带者	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs113993960	-/-	有害突变纯合	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs121908767	ATAGTG/ATAGTG	正常基因型	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs121908767	ATAGTG/-	有害突变携带者	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs121908767	-/-	有害突变纯合	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs121908755	G/G	正常基因型	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs121908755	G/A	有害突变携带者	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs121908755	A/A	有害突变纯合	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs121908748	G/G	正常基因型	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs121908748	G/A	有害突变携带者	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs121908748	A/A	有害突变纯合	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs113993960	CTT/CTT	正常基因型	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs113993960	CTT/-	有害突变携带者	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs113993960	-/-	有害突变纯合	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs113993958	G/G	正常基因型	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs113993958	C/G	有害突变携带者	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
囊性纤维化	常染色体隐性	CFTR	rs113993958	C/C	有害突变纯合	Kerem B， et al. Identification of the cystic fibrosis gene: genetic analysis. 1989van Barneveld A， et al. CFTR protein analysis of splice site mutation 2789+5 G-A. 2008Mainz J， et al. Cystic fibrosis in 65- and 67-year-old siblings. Clinical feature and nasal potential difference measurement in patients with genotypes F508del and 2789+5G-->A. 2006McKone EF， et al. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. 2003Visich A， et al. Complete screening of the CFTR gene in Argentine cystic fibrosis patients. 2002Stuhrmann M， et al. Detection of 100% of the CFTR mutations in 63 CF families from Tyrol. 1997Bernardino AL， et al. Molecular analysis in Brazilian cystic fibrosis patients reveals five novel mutations. 2347Angelicheva D， et al. Cystic fibrosis mutations and associated haplotypes in Bulgaria - a comparative population genetic study. 1997Keyeux G， et al. CFTR mutations in patients from Colombia: implications for local and regional molecular diagnosis programs. 2003Guilloud-Bataille M， et al. Cystic fibrosis mutations: report from the French Registry. The Clinical Centers of the CF. 2000D?rk T， et al. Detection of more than 50 different CFTR mutations in a large group of German cystic fibrosis patients. 1994Kanavakis E， et al. Cystic fibrosis in Greece: molecular diagnosis， haplotypes， prenatal diagnosis and carrier identification amongst high-risk individuals. 2003Alibakhshi R， et al. Analysis of the CFTR gene in Iranian cystic fibrosis patients: identification of eight novel mutations. 2008Bonizzato A， et al. Analysis of the complete coding region of the CFTR gene in a cohort of CF patients from north-eastern Italy: identification of 90% of the mutations. 1995Desgeorges M， et al. Cystic fibrosis in Lebanon: distribution of CFTR mutations among Arab communities. 1997Cartault F， et al. Detection of more than 91% cystic fibrosis mutations in a sample of the population from Reunion Island and identification of two novel mutations (A309G， S1255L) and one novel polymorphism (L49L) 1998Radivojevic D， et al. Spectrum of cystic fibrosis mutations in Serbia and Montenegro and strategy for prenatal diagnosis. 2004Alonso MJ， et al. Spectrum of mutations in the CFTR gene in cystic fibrosis patients of Spanish ancestry. 2007Gómez-Llorente MA， et al. Analysis of 31 CFTR mutations in 55 families from the South of Spain. 2001Kilin? MO， et al. Highest heterogeneity for cystic fibrosis: 36 mutations account for 75% of all CF chromosomes in Turkish patients. 2002Luzardo G， et al. Cystic fibrosis in Uruguay. 2002Kerem BS， et al. DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. 1989Quint A， et al. Mutation spectrum in Jewish cystic fibrosis patients in Israel: implication to carrier screening. 2005Spitzer E， et al. Identification of a new cystic fibrosis transmembrane regulator mutation in a severely affected patient. 2002Bobadilla JL， et al. Cystic fibrosis: a worldwide analysis of CFTR mutations--correlation with incidence data and application to screening. 2002Watson MS， et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. 2004Sugarman EA， et al. CFTR mutation distribution among U.S. Hispanic and African American individuals: evaluation in cystic fibrosis patient and carrier screening populations. 2004Castellani C， et al. Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. 2008Heim RA， et al. Improved detection of cystic fibrosis mutations in the heterogeneous U.S. population using an expanded， pan-ethnic mutation panel. 2001Massie RJ， et al. Intron-8 polythymidine sequence in Australasian individuals with CF mutations R117H and R117C. 2001Rozen R， et al. Cystic fibrosis mutations in French Canadians: three CFTR mutations are relatively frequent in a Quebec population with an elevated incidence of cystic fibrosis. 1992Ochoa Urdangaráin O， et al. [Renal abscess. Medical treatment]. 1991	GENETIC_DISEASE			消化呼吸系统
二氢嘧啶脱氢酶缺乏症	常染色体隐性	DPYD	rs3918290	C/C	正常基因型	Ezzeldin H， et al. Dihydropyrimidine dehydrogenase deficiency， a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. 2004Galván CA， et al. Genetic profiling of GSTP1， DPYD， FCGR2A， FCGR3A and CCND1 genes in an Argentinian population. 2011Ekstr?m PO， et al. Technology to accelerate pangenomic scanning for unknown point mutations in exonic sequences: cycling temperature capillary electrophoresis (CTCE). 2007Dai Z， et al. Genotyping panel for assessing response to cancer chemotherapy. 2008Ramos E， et al. Pharmacogenomics， ancestry and clinical decision making for global populations. 2014	GENETIC_DISEASE			遗传代谢
二氢嘧啶脱氢酶缺乏症	常染色体隐性	DPYD	rs3918290	C/T	有害突变携带者	Ezzeldin H， et al. Dihydropyrimidine dehydrogenase deficiency， a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. 2004Galván CA， et al. Genetic profiling of GSTP1， DPYD， FCGR2A， FCGR3A and CCND1 genes in an Argentinian population. 2011Ekstr?m PO， et al. Technology to accelerate pangenomic scanning for unknown point mutations in exonic sequences: cycling temperature capillary electrophoresis (CTCE). 2007Dai Z， et al. Genotyping panel for assessing response to cancer chemotherapy. 2008Ramos E， et al. Pharmacogenomics， ancestry and clinical decision making for global populations. 2014	GENETIC_DISEASE			遗传代谢
二氢嘧啶脱氢酶缺乏症	常染色体隐性	DPYD	rs3918290	T/T	有害突变纯合	Ezzeldin H， et al. Dihydropyrimidine dehydrogenase deficiency， a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. 2004Galván CA， et al. Genetic profiling of GSTP1， DPYD， FCGR2A， FCGR3A and CCND1 genes in an Argentinian population. 2011Ekstr?m PO， et al. Technology to accelerate pangenomic scanning for unknown point mutations in exonic sequences: cycling temperature capillary electrophoresis (CTCE). 2007Dai Z， et al. Genotyping panel for assessing response to cancer chemotherapy. 2008Ramos E， et al. Pharmacogenomics， ancestry and clinical decision making for global populations. 2014	GENETIC_DISEASE			遗传代谢
α-1抗胰蛋白酶缺乏	常染色体共显性	SERPINA1	rs17580	T/T	正常基因型	Fujimoto K， et al. Polymorphism of SERPINE2 gene is associated with pulmonary emphysema in consecutive autopsy cases. 2010Mihalache F， et al. Heterozygosity for the alpha1-antitrypsin Z allele may confer genetic risk of cholangiocarcinoma. 2011Lee PL， et al. Genetic polymorphisms and susceptibility to lung disease. 2006Kok KF， et al. Prevalence of genetic polymorphisms in the promoter region of the alpha-1 antitrypsin (SERPINA1) gene in chronic liver disease: a case control study. 2010Ferrarotti I， et al. Serum levels and genotype distribution of α1-antitrypsin in the general population. 2012Yoshida A， et al. Molecular abnormality of PI S variant of human alpha1-antitrypsin. 1977Curiel D， et al. Alpha 1-antitrypsin deficiency caused by the alpha 1-antitrypsin Nullmattawa gene. An insertion mutation rendering the alpha 1-antitrypsin gene incapable of producing alpha 1-antitrypsin. 1989Thun GA， et al. SERPINA1 PiZ and PiS heterozygotes and lung function decline in the SAPALDIA cohort. 2012Pérez-Rubio G， et al. Prevalence of alpha-1 antitrypsin high-risk variants in Mexican mestizo population and their association with lung function values. 2015Brantly M， et al. Repair of the secretion defect in the Z form of alpha 1-antitrypsin by addition of a second mutation. 1988Hendrick SJ， et al. Alpha 1-antitrypsin deficiency associated with panniculitis. 1988Dycaico MJ， et al. Neonatal hepatitis induced by alpha 1-antitrypsin: a transgenic mouse model. 1988	GENETIC_DISEASE			遗传代谢
α-1抗胰蛋白酶缺乏	常染色体共显性	SERPINA1	rs17580	T/A	有害突变携带者	Fujimoto K， et al. Polymorphism of SERPINE2 gene is associated with pulmonary emphysema in consecutive autopsy cases. 2010Mihalache F， et al. Heterozygosity for the alpha1-antitrypsin Z allele may confer genetic risk of cholangiocarcinoma. 2011Lee PL， et al. Genetic polymorphisms and susceptibility to lung disease. 2006Kok KF， et al. Prevalence of genetic polymorphisms in the promoter region of the alpha-1 antitrypsin (SERPINA1) gene in chronic liver disease: a case control study. 2010Ferrarotti I， et al. Serum levels and genotype distribution of α1-antitrypsin in the general population. 2012Yoshida A， et al. Molecular abnormality of PI S variant of human alpha1-antitrypsin. 1977Curiel D， et al. Alpha 1-antitrypsin deficiency caused by the alpha 1-antitrypsin Nullmattawa gene. An insertion mutation rendering the alpha 1-antitrypsin gene incapable of producing alpha 1-antitrypsin. 1989Thun GA， et al. SERPINA1 PiZ and PiS heterozygotes and lung function decline in the SAPALDIA cohort. 2012Pérez-Rubio G， et al. Prevalence of alpha-1 antitrypsin high-risk variants in Mexican mestizo population and their association with lung function values. 2015Brantly M， et al. Repair of the secretion defect in the Z form of alpha 1-antitrypsin by addition of a second mutation. 1988Hendrick SJ， et al. Alpha 1-antitrypsin deficiency associated with panniculitis. 1988Dycaico MJ， et al. Neonatal hepatitis induced by alpha 1-antitrypsin: a transgenic mouse model. 1988	GENETIC_DISEASE			遗传代谢
α-1抗胰蛋白酶缺乏	常染色体共显性	SERPINA1	rs17580	A/A	有害突变纯合	Fujimoto K， et al. Polymorphism of SERPINE2 gene is associated with pulmonary emphysema in consecutive autopsy cases. 2010Mihalache F， et al. Heterozygosity for the alpha1-antitrypsin Z allele may confer genetic risk of cholangiocarcinoma. 2011Lee PL， et al. Genetic polymorphisms and susceptibility to lung disease. 2006Kok KF， et al. Prevalence of genetic polymorphisms in the promoter region of the alpha-1 antitrypsin (SERPINA1) gene in chronic liver disease: a case control study. 2010Ferrarotti I， et al. Serum levels and genotype distribution of α1-antitrypsin in the general population. 2012Yoshida A， et al. Molecular abnormality of PI S variant of human alpha1-antitrypsin. 1977Curiel D， et al. Alpha 1-antitrypsin deficiency caused by the alpha 1-antitrypsin Nullmattawa gene. An insertion mutation rendering the alpha 1-antitrypsin gene incapable of producing alpha 1-antitrypsin. 1989Thun GA， et al. SERPINA1 PiZ and PiS heterozygotes and lung function decline in the SAPALDIA cohort. 2012Pérez-Rubio G， et al. Prevalence of alpha-1 antitrypsin high-risk variants in Mexican mestizo population and their association with lung function values. 2015Brantly M， et al. Repair of the secretion defect in the Z form of alpha 1-antitrypsin by addition of a second mutation. 1988Hendrick SJ， et al. Alpha 1-antitrypsin deficiency associated with panniculitis. 1988Dycaico MJ， et al. Neonatal hepatitis induced by alpha 1-antitrypsin: a transgenic mouse model. 1988	GENETIC_DISEASE			遗传代谢
α-1抗胰蛋白酶缺乏	常染色体共显性	SERPINA1	rs28929474	C/C	正常基因型	Fujimoto K， et al. Polymorphism of SERPINE2 gene is associated with pulmonary emphysema in consecutive autopsy cases. 2010Mihalache F， et al. Heterozygosity for the alpha1-antitrypsin Z allele may confer genetic risk of cholangiocarcinoma. 2011Lee PL， et al. Genetic polymorphisms and susceptibility to lung disease. 2006Kok KF， et al. Prevalence of genetic polymorphisms in the promoter region of the alpha-1 antitrypsin (SERPINA1) gene in chronic liver disease: a case control study. 2010Ferrarotti I， et al. Serum levels and genotype distribution of α1-antitrypsin in the general population. 2012Yoshida A， et al. Molecular abnormality of PI S variant of human alpha1-antitrypsin. 1977Curiel D， et al. Alpha 1-antitrypsin deficiency caused by the alpha 1-antitrypsin Nullmattawa gene. An insertion mutation rendering the alpha 1-antitrypsin gene incapable of producing alpha 1-antitrypsin. 1989Thun GA， et al. SERPINA1 PiZ and PiS heterozygotes and lung function decline in the SAPALDIA cohort. 2012Pérez-Rubio G， et al. Prevalence of alpha-1 antitrypsin high-risk variants in Mexican mestizo population and their association with lung function values. 2015Brantly M， et al. Repair of the secretion defect in the Z form of alpha 1-antitrypsin by addition of a second mutation. 1988Hendrick SJ， et al. Alpha 1-antitrypsin deficiency associated with panniculitis. 1988Dycaico MJ， et al. Neonatal hepatitis induced by alpha 1-antitrypsin: a transgenic mouse model. 1988	GENETIC_DISEASE			遗传代谢
α-1抗胰蛋白酶缺乏	常染色体共显性	SERPINA1	rs28929474	C/T	有害突变携带者	Fujimoto K， et al. Polymorphism of SERPINE2 gene is associated with pulmonary emphysema in consecutive autopsy cases. 2010Mihalache F， et al. Heterozygosity for the alpha1-antitrypsin Z allele may confer genetic risk of cholangiocarcinoma. 2011Lee PL， et al. Genetic polymorphisms and susceptibility to lung disease. 2006Kok KF， et al. Prevalence of genetic polymorphisms in the promoter region of the alpha-1 antitrypsin (SERPINA1) gene in chronic liver disease: a case control study. 2010Ferrarotti I， et al. Serum levels and genotype distribution of α1-antitrypsin in the general population. 2012Yoshida A， et al. Molecular abnormality of PI S variant of human alpha1-antitrypsin. 1977Curiel D， et al. Alpha 1-antitrypsin deficiency caused by the alpha 1-antitrypsin Nullmattawa gene. An insertion mutation rendering the alpha 1-antitrypsin gene incapable of producing alpha 1-antitrypsin. 1989Thun GA， et al. SERPINA1 PiZ and PiS heterozygotes and lung function decline in the SAPALDIA cohort. 2012Pérez-Rubio G， et al. Prevalence of alpha-1 antitrypsin high-risk variants in Mexican mestizo population and their association with lung function values. 2015Brantly M， et al. Repair of the secretion defect in the Z form of alpha 1-antitrypsin by addition of a second mutation. 1988Hendrick SJ， et al. Alpha 1-antitrypsin deficiency associated with panniculitis. 1988Dycaico MJ， et al. Neonatal hepatitis induced by alpha 1-antitrypsin: a transgenic mouse model. 1988	GENETIC_DISEASE			遗传代谢
α-1抗胰蛋白酶缺乏	常染色体共显性	SERPINA1	rs28929474	T/T	有害突变纯合	Fujimoto K， et al. Polymorphism of SERPINE2 gene is associated with pulmonary emphysema in consecutive autopsy cases. 2010Mihalache F， et al. Heterozygosity for the alpha1-antitrypsin Z allele may confer genetic risk of cholangiocarcinoma. 2011Lee PL， et al. Genetic polymorphisms and susceptibility to lung disease. 2006Kok KF， et al. Prevalence of genetic polymorphisms in the promoter region of the alpha-1 antitrypsin (SERPINA1) gene in chronic liver disease: a case control study. 2010Ferrarotti I， et al. Serum levels and genotype distribution of α1-antitrypsin in the general population. 2012Yoshida A， et al. Molecular abnormality of PI S variant of human alpha1-antitrypsin. 1977Curiel D， et al. Alpha 1-antitrypsin deficiency caused by the alpha 1-antitrypsin Nullmattawa gene. An insertion mutation rendering the alpha 1-antitrypsin gene incapable of producing alpha 1-antitrypsin. 1989Thun GA， et al. SERPINA1 PiZ and PiS heterozygotes and lung function decline in the SAPALDIA cohort. 2012Pérez-Rubio G， et al. Prevalence of alpha-1 antitrypsin high-risk variants in Mexican mestizo population and their association with lung function values. 2015Brantly M， et al. Repair of the secretion defect in the Z form of alpha 1-antitrypsin by addition of a second mutation. 1988Hendrick SJ， et al. Alpha 1-antitrypsin deficiency associated with panniculitis. 1988Dycaico MJ， et al. Neonatal hepatitis induced by alpha 1-antitrypsin: a transgenic mouse model. 1988	GENETIC_DISEASE			遗传代谢
葡萄糖-6-磷酸脱氢酶缺乏症	伴X染色体不完全显性	G6PD	rs1050828	C/C	正常基因型	Peters AL， et al. Glucose-6-phosphate dehydrogenase deficiency and malaria: cytochemical detection of heterozygous G6PD deficiency in women. 2009Eid NA， et al. Candidate malaria susceptibility/protective SNPs in hospital and population-based studies: the effect of sub-structuring. 2010Lo KS， et al. Genetic association analysis highlights new loci that modulate hematological trait variation in Caucasians and African Americans. 2011Chen Z， et al. Genome-wide association analysis of red blood cell traits in African Americans: the COGENT Network. 2013Ding K， et al. Genetic variants that confer resistance to malaria are associated with red blood cell traits in African-Americans: an electronic medical record-based genome-wide association study. 2013Kariuki SM， et al. The genetic risk of acute seizures in African children with falciparum malaria. 2013Walther M， et al. HMOX1 gene promoter alleles and high HO-1 levels are associated with severe malaria in Gambian children. 2012Al-Sweedan SA， et al. Molecular characterization of glucose-6-phosphate dehydrogenase deficiency among Jordanians. 2012Carter N， et al. Frequency of glucose-6-phosphate dehydrogenase deficiency in malaria patients from six African countries enrolled in two randomized anti-malarial clinical trials. 2011	GENETIC_DISEASE			血液系统
葡萄糖-6-磷酸脱氢酶缺乏症	伴X染色体不完全显性	G6PD	rs1050828	C/T	有害突变携带者	Peters AL， et al. Glucose-6-phosphate dehydrogenase deficiency and malaria: cytochemical detection of heterozygous G6PD deficiency in women. 2009Eid NA， et al. Candidate malaria susceptibility/protective SNPs in hospital and population-based studies: the effect of sub-structuring. 2010Lo KS， et al. Genetic association analysis highlights new loci that modulate hematological trait variation in Caucasians and African Americans. 2011Chen Z， et al. Genome-wide association analysis of red blood cell traits in African Americans: the COGENT Network. 2013Ding K， et al. Genetic variants that confer resistance to malaria are associated with red blood cell traits in African-Americans: an electronic medical record-based genome-wide association study. 2013Kariuki SM， et al. The genetic risk of acute seizures in African children with falciparum malaria. 2013Walther M， et al. HMOX1 gene promoter alleles and high HO-1 levels are associated with severe malaria in Gambian children. 2012Al-Sweedan SA， et al. Molecular characterization of glucose-6-phosphate dehydrogenase deficiency among Jordanians. 2012Carter N， et al. Frequency of glucose-6-phosphate dehydrogenase deficiency in malaria patients from six African countries enrolled in two randomized anti-malarial clinical trials. 2011	GENETIC_DISEASE			血液系统
葡萄糖-6-磷酸脱氢酶缺乏症	伴X染色体不完全显性	G6PD	rs1050828	T/T	有害突变纯合	Peters AL， et al. Glucose-6-phosphate dehydrogenase deficiency and malaria: cytochemical detection of heterozygous G6PD deficiency in women. 2009Eid NA， et al. Candidate malaria susceptibility/protective SNPs in hospital and population-based studies: the effect of sub-structuring. 2010Lo KS， et al. Genetic association analysis highlights new loci that modulate hematological trait variation in Caucasians and African Americans. 2011Chen Z， et al. Genome-wide association analysis of red blood cell traits in African Americans: the COGENT Network. 2013Ding K， et al. Genetic variants that confer resistance to malaria are associated with red blood cell traits in African-Americans: an electronic medical record-based genome-wide association study. 2013Kariuki SM， et al. The genetic risk of acute seizures in African children with falciparum malaria. 2013Walther M， et al. HMOX1 gene promoter alleles and high HO-1 levels are associated with severe malaria in Gambian children. 2012Al-Sweedan SA， et al. Molecular characterization of glucose-6-phosphate dehydrogenase deficiency among Jordanians. 2012Carter N， et al. Frequency of glucose-6-phosphate dehydrogenase deficiency in malaria patients from six African countries enrolled in two randomized anti-malarial clinical trials. 2011	GENETIC_DISEASE			血液系统
葡萄糖-6-磷酸脱氢酶缺乏症	伴X染色体不完全显性	G6PD	rs1050829	C/C	正常基因型	Peters AL， et al. Glucose-6-phosphate dehydrogenase deficiency and malaria: cytochemical detection of heterozygous G6PD deficiency in women. 2009Eid NA， et al. Candidate malaria susceptibility/protective SNPs in hospital and population-based studies: the effect of sub-structuring. 2010Lo KS， et al. Genetic association analysis highlights new loci that modulate hematological trait variation in Caucasians and African Americans. 2011Chen Z， et al. Genome-wide association analysis of red blood cell traits in African Americans: the COGENT Network. 2013Ding K， et al. Genetic variants that confer resistance to malaria are associated with red blood cell traits in African-Americans: an electronic medical record-based genome-wide association study. 2013Kariuki SM， et al. The genetic risk of acute seizures in African children with falciparum malaria. 2013Walther M， et al. HMOX1 gene promoter alleles and high HO-1 levels are associated with severe malaria in Gambian children. 2012Al-Sweedan SA， et al. Molecular characterization of glucose-6-phosphate dehydrogenase deficiency among Jordanians. 2012Carter N， et al. Frequency of glucose-6-phosphate dehydrogenase deficiency in malaria patients from six African countries enrolled in two randomized anti-malarial clinical trials. 2011	GENETIC_DISEASE			血液系统
葡萄糖-6-磷酸脱氢酶缺乏症	伴X染色体不完全显性	G6PD	rs1050829	T/C	有害突变携带者	Peters AL， et al. Glucose-6-phosphate dehydrogenase deficiency and malaria: cytochemical detection of heterozygous G6PD deficiency in women. 2009Eid NA， et al. Candidate malaria susceptibility/protective SNPs in hospital and population-based studies: the effect of sub-structuring. 2010Lo KS， et al. Genetic association analysis highlights new loci that modulate hematological trait variation in Caucasians and African Americans. 2011Chen Z， et al. Genome-wide association analysis of red blood cell traits in African Americans: the COGENT Network. 2013Ding K， et al. Genetic variants that confer resistance to malaria are associated with red blood cell traits in African-Americans: an electronic medical record-based genome-wide association study. 2013Kariuki SM， et al. The genetic risk of acute seizures in African children with falciparum malaria. 2013Walther M， et al. HMOX1 gene promoter alleles and high HO-1 levels are associated with severe malaria in Gambian children. 2012Al-Sweedan SA， et al. Molecular characterization of glucose-6-phosphate dehydrogenase deficiency among Jordanians. 2012Carter N， et al. Frequency of glucose-6-phosphate dehydrogenase deficiency in malaria patients from six African countries enrolled in two randomized anti-malarial clinical trials. 2011	GENETIC_DISEASE			血液系统
葡萄糖-6-磷酸脱氢酶缺乏症	伴X染色体不完全显性	G6PD	rs1050829	T/T	有害突变纯合	Peters AL， et al. Glucose-6-phosphate dehydrogenase deficiency and malaria: cytochemical detection of heterozygous G6PD deficiency in women. 2009Eid NA， et al. Candidate malaria susceptibility/protective SNPs in hospital and population-based studies: the effect of sub-structuring. 2010Lo KS， et al. Genetic association analysis highlights new loci that modulate hematological trait variation in Caucasians and African Americans. 2011Chen Z， et al. Genome-wide association analysis of red blood cell traits in African Americans: the COGENT Network. 2013Ding K， et al. Genetic variants that confer resistance to malaria are associated with red blood cell traits in African-Americans: an electronic medical record-based genome-wide association study. 2013Kariuki SM， et al. The genetic risk of acute seizures in African children with falciparum malaria. 2013Walther M， et al. HMOX1 gene promoter alleles and high HO-1 levels are associated with severe malaria in Gambian children. 2012Al-Sweedan SA， et al. Molecular characterization of glucose-6-phosphate dehydrogenase deficiency among Jordanians. 2012Carter N， et al. Frequency of glucose-6-phosphate dehydrogenase deficiency in malaria patients from six African countries enrolled in two randomized anti-malarial clinical trials. 2011	GENETIC_DISEASE			血液系统
酪氨酸血症 I型	常染色体隐性	FAH	rs80338898	C/C	正常基因型	Bergman AJ， et al. Spectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type 1 patients in northwestern Europe and Mediterranean countries. 2015Elpeleg ON， et al. Mutation analysis of the FAH gene in Israeli patients with tyrosinemia type I. 2002St-Louis M， et al. Identification of a stop mutation in five Finnish patients suffering from hereditary tyrosinemia type I. 1994St-Louis M， et al. Simple detection of a (Finnish) hereditary tyrosinemia type 1 mutation. 2015	GENETIC_DISEASE			遗传代谢
酪氨酸血症 I型	常染色体隐性	FAH	rs80338898	C/T	有害突变携带者	Bergman AJ， et al. Spectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type 1 patients in northwestern Europe and Mediterranean countries. 2015Elpeleg ON， et al. Mutation analysis of the FAH gene in Israeli patients with tyrosinemia type I. 2002St-Louis M， et al. Identification of a stop mutation in five Finnish patients suffering from hereditary tyrosinemia type I. 1994St-Louis M， et al. Simple detection of a (Finnish) hereditary tyrosinemia type 1 mutation. 2015	GENETIC_DISEASE			遗传代谢
酪氨酸血症 I型	常染色体隐性	FAH	rs80338898	T/T	有害突变纯合	Bergman AJ， et al. Spectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type 1 patients in northwestern Europe and Mediterranean countries. 2015Elpeleg ON， et al. Mutation analysis of the FAH gene in Israeli patients with tyrosinemia type I. 2002St-Louis M， et al. Identification of a stop mutation in five Finnish patients suffering from hereditary tyrosinemia type I. 1994St-Louis M， et al. Simple detection of a (Finnish) hereditary tyrosinemia type 1 mutation. 2015	GENETIC_DISEASE			遗传代谢
酪氨酸血症 I型	常染色体隐性	FAH	rs80338899	G/G	正常基因型	Bergman AJ， et al. Spectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type 1 patients in northwestern Europe and Mediterranean countries. 2015Elpeleg ON， et al. Mutation analysis of the FAH gene in Israeli patients with tyrosinemia type I. 2002St-Louis M， et al. Identification of a stop mutation in five Finnish patients suffering from hereditary tyrosinemia type I. 1994St-Louis M， et al. Simple detection of a (Finnish) hereditary tyrosinemia type 1 mutation. 2015	GENETIC_DISEASE			遗传代谢
酪氨酸血症 I型	常染色体隐性	FAH	rs80338899	G/A	有害突变携带者	Bergman AJ， et al. Spectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type 1 patients in northwestern Europe and Mediterranean countries. 2015Elpeleg ON， et al. Mutation analysis of the FAH gene in Israeli patients with tyrosinemia type I. 2002St-Louis M， et al. Identification of a stop mutation in five Finnish patients suffering from hereditary tyrosinemia type I. 1994St-Louis M， et al. Simple detection of a (Finnish) hereditary tyrosinemia type 1 mutation. 2015	GENETIC_DISEASE			遗传代谢
酪氨酸血症 I型	常染色体隐性	FAH	rs80338899	A/A	有害突变纯合	Bergman AJ， et al. Spectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type 1 patients in northwestern Europe and Mediterranean countries. 2015Elpeleg ON， et al. Mutation analysis of the FAH gene in Israeli patients with tyrosinemia type I. 2002St-Louis M， et al. Identification of a stop mutation in five Finnish patients suffering from hereditary tyrosinemia type I. 1994St-Louis M， et al. Simple detection of a (Finnish) hereditary tyrosinemia type 1 mutation. 2015	GENETIC_DISEASE			遗传代谢
戴萨克斯症	常染色体隐性	HEXA	rs121907970	G/G	正常基因型	Karpati M， et al. Specific mutations in the HEXA gene among Iraqi Jewish Tay-Sachs disease carriers: dating of founder ancestor. 2004	GENETIC_DISEASE			神经系统
戴萨克斯症	常染色体隐性	HEXA	rs121907970	G/A	有害突变携带者	Karpati M， et al. Specific mutations in the HEXA gene among Iraqi Jewish Tay-Sachs disease carriers: dating of founder ancestor. 2004	GENETIC_DISEASE			神经系统
戴萨克斯症	常染色体隐性	HEXA	rs121907970	A/A	有害突变纯合	Karpati M， et al. Specific mutations in the HEXA gene among Iraqi Jewish Tay-Sachs disease carriers: dating of founder ancestor. 2004	GENETIC_DISEASE			神经系统
戴萨克斯症	常染色体隐性	HEXA	rs147324677	C/C	正常基因型	Karpati M， et al. Specific mutations in the HEXA gene among Iraqi Jewish Tay-Sachs disease carriers: dating of founder ancestor. 2004	GENETIC_DISEASE			神经系统
戴萨克斯症	常染色体隐性	HEXA	rs147324677	C/G	有害突变携带者	Karpati M， et al. Specific mutations in the HEXA gene among Iraqi Jewish Tay-Sachs disease carriers: dating of founder ancestor. 2004	GENETIC_DISEASE			神经系统
戴萨克斯症	常染色体隐性	HEXA	rs147324677	G/G	有害突变纯合	Karpati M， et al. Specific mutations in the HEXA gene among Iraqi Jewish Tay-Sachs disease carriers: dating of founder ancestor. 2004	GENETIC_DISEASE			神经系统
戴萨克斯症	常染色体隐性	HEXA	rs28940871	G/G	正常基因型	Karpati M， et al. Specific mutations in the HEXA gene among Iraqi Jewish Tay-Sachs disease carriers: dating of founder ancestor. 2004	GENETIC_DISEASE			神经系统
戴萨克斯症	常染色体隐性	HEXA	rs28940871	G/C	有害突变携带者	Karpati M， et al. Specific mutations in the HEXA gene among Iraqi Jewish Tay-Sachs disease carriers: dating of founder ancestor. 2004	GENETIC_DISEASE			神经系统
戴萨克斯症	常染色体隐性	HEXA	rs28940871	C/C	有害突变纯合	Karpati M， et al. Specific mutations in the HEXA gene among Iraqi Jewish Tay-Sachs disease carriers: dating of founder ancestor. 2004	GENETIC_DISEASE			神经系统
戴萨克斯症	常染色体隐性	HEXA	rs76173977	C/C	正常基因型	Karpati M， et al. Specific mutations in the HEXA gene among Iraqi Jewish Tay-Sachs disease carriers: dating of founder ancestor. 2004	GENETIC_DISEASE			神经系统
戴萨克斯症	常染色体隐性	HEXA	rs76173977	C/T	有害突变携带者	Karpati M， et al. Specific mutations in the HEXA gene among Iraqi Jewish Tay-Sachs disease carriers: dating of founder ancestor. 2004	GENETIC_DISEASE			神经系统
戴萨克斯症	常染色体隐性	HEXA	rs76173977	T/T	有害突变纯合	Karpati M， et al. Specific mutations in the HEXA gene among Iraqi Jewish Tay-Sachs disease carriers: dating of founder ancestor. 2004	GENETIC_DISEASE			神经系统
肢近端型点状软骨发育不良	常染色体隐性	PEX7	rs1805137	T/T	正常基因型		GENETIC_DISEASE			其他
肢近端型点状软骨发育不良	常染色体隐性	PEX7	rs1805137	T/A	有害突变携带者		GENETIC_DISEASE			其他
肢近端型点状软骨发育不良	常染色体隐性	PEX7	rs1805137	A/A	有害突变纯合		GENETIC_DISEASE			其他
凝血因子XI缺陷症	常染色体隐性	F9	rs104894807	T/T	正常基因型	"""Rogaev EI， et al. Genotype analysis identifies the cause of the """"""""royal disease"""""""". 2009"""	GENETIC_DISEASE			血液系统
凝血因子XI缺陷症	常染色体隐性	F9	rs104894807	T/C	有害突变携带者	"""Rogaev EI， et al. Genotype analysis identifies the cause of the """"""""royal disease"""""""". 2009"""	GENETIC_DISEASE			血液系统
凝血因子XI缺陷症	常染色体隐性	F9	rs104894807	C/C	有害突变纯合	"""Rogaev EI， et al. Genotype analysis identifies the cause of the """"""""royal disease"""""""". 2009"""	GENETIC_DISEASE			血液系统
凝血因子XI缺陷症	常染色体隐性	F11	rs121965063	G/G	正常基因型	"""Rogaev EI， et al. Genotype analysis identifies the cause of the """"""""royal disease"""""""". 2009"""	GENETIC_DISEASE			血液系统
凝血因子XI缺陷症	常染色体隐性	F11	rs121965063	G/T	有害突变携带者	"""Rogaev EI， et al. Genotype analysis identifies the cause of the """"""""royal disease"""""""". 2009"""	GENETIC_DISEASE			血液系统
凝血因子XI缺陷症	常染色体隐性	F11	rs121965063	T/T	有害突变纯合	"""Rogaev EI， et al. Genotype analysis identifies the cause of the """"""""royal disease"""""""". 2009"""	GENETIC_DISEASE			血液系统
凝血因子XI缺陷症	常染色体隐性	F11	rs121965064	T/T	正常基因型	"""Rogaev EI， et al. Genotype analysis identifies the cause of the """"""""royal disease"""""""". 2009"""	GENETIC_DISEASE			血液系统
凝血因子XI缺陷症	常染色体隐性	F11	rs121965064	T/C	有害突变携带者	"""Rogaev EI， et al. Genotype analysis identifies the cause of the """"""""royal disease"""""""". 2009"""	GENETIC_DISEASE			血液系统
凝血因子XI缺陷症	常染色体隐性	F11	rs121965064	C/C	有害突变纯合	"""Rogaev EI， et al. Genotype analysis identifies the cause of the """"""""royal disease"""""""". 2009"""	GENETIC_DISEASE			血液系统
凝血因子XI缺陷症	常染色体隐性	F9	rs398122990	A/A	正常基因型	"""Rogaev EI， et al. Genotype analysis identifies the cause of the """"""""royal disease"""""""". 2009"""	GENETIC_DISEASE			血液系统
凝血因子XI缺陷症	常染色体隐性	F9	rs398122990	A/G	有害突变携带者	"""Rogaev EI， et al. Genotype analysis identifies the cause of the """"""""royal disease"""""""". 2009"""	GENETIC_DISEASE			血液系统
凝血因子XI缺陷症	常染色体隐性	F9	rs398122990	G/G	有害突变纯合	"""Rogaev EI， et al. Genotype analysis identifies the cause of the """"""""royal disease"""""""". 2009"""	GENETIC_DISEASE			血液系统
甲状腺肿-耳聋综合征	常染色体隐性	SLC26A4	rs111033199	G/G	正常基因型	Murray RH， et al. Little evidence to suggest end to physician shortage. 1976Van Hauwe P， et al. Two frequent missense mutations in Pendred syndrome. 1998Coyle B， et al. Molecular analysis of the PDS gene in Pendred syndrome. 1998Campbell C， et al. Pendred syndrome， DFNB4， and PDS/SLC26A4 identification of eight novel mutations and possible genotype-phenotype correlations. 2001Gonzalez Trevino O， et al. Clinical and molecular analysis of three Mexican families with Pendred's syndrome. 2001Pryor SP， et al. SLC26A4/PDS genotype-phenotype correlation in hearing loss with enlargement of the vestibular aqueduct (EVA): evidence that Pendred syndrome and non-syndromic EVA are distinct clinical and genetic entities. 2005Lesnik EA， et al. [Reaction capabilities and structure of poly(rG) and poly(rG)-poly(rC) in solution by the method of the kinetics of hydrogen ion exchange]. 1976Borck G， et al. Mutations in the PDS gene in German families with Pendred's syndrome: V138F is a founder mutation. 2003Prasad S， et al. Pendred syndrome and DFNB4-mutation screening of SLC26A4 by denaturing high-performance liquid chromatography and the identification of eleven novel mutations. 2004Blons H， et al. Screening of SLC26A4 (PDS) gene in Pendred's syndrome: a large spectrum of mutations in France and phenotypic heterogeneity. 2004Napiontek U， et al. Intrafamilial variability of the deafness and goiter phenotype in Pendred syndrome caused by a T416P mutation in the SLC26A4 gene. 2004Yoon JS， et al. Heterogeneity in the processing defect of SLC26A4 mutants. 2008Reardon W， et al. Enlarged vestibular aqueduct: a radiological marker of pendred syndrome， and mutation of the PDS gene. 2000	GENETIC_DISEASE			耳鼻喉
甲状腺肿-耳聋综合征	常染色体隐性	SLC26A4	rs111033199	G/T	有害突变携带者	Murray RH， et al. Little evidence to suggest end to physician shortage. 1976Van Hauwe P， et al. Two frequent missense mutations in Pendred syndrome. 1998Coyle B， et al. Molecular analysis of the PDS gene in Pendred syndrome. 1998Campbell C， et al. Pendred syndrome， DFNB4， and PDS/SLC26A4 identification of eight novel mutations and possible genotype-phenotype correlations. 2001Gonzalez Trevino O， et al. Clinical and molecular analysis of three Mexican families with Pendred's syndrome. 2001Pryor SP， et al. SLC26A4/PDS genotype-phenotype correlation in hearing loss with enlargement of the vestibular aqueduct (EVA): evidence that Pendred syndrome and non-syndromic EVA are distinct clinical and genetic entities. 2005Lesnik EA， et al. [Reaction capabilities and structure of poly(rG) and poly(rG)-poly(rC) in solution by the method of the kinetics of hydrogen ion exchange]. 1976Borck G， et al. Mutations in the PDS gene in German families with Pendred's syndrome: V138F is a founder mutation. 2003Prasad S， et al. Pendred syndrome and DFNB4-mutation screening of SLC26A4 by denaturing high-performance liquid chromatography and the identification of eleven novel mutations. 2004Blons H， et al. Screening of SLC26A4 (PDS) gene in Pendred's syndrome: a large spectrum of mutations in France and phenotypic heterogeneity. 2004Napiontek U， et al. Intrafamilial variability of the deafness and goiter phenotype in Pendred syndrome caused by a T416P mutation in the SLC26A4 gene. 2004Yoon JS， et al. Heterogeneity in the processing defect of SLC26A4 mutants. 2008Reardon W， et al. Enlarged vestibular aqueduct: a radiological marker of pendred syndrome， and mutation of the PDS gene. 2000	GENETIC_DISEASE			耳鼻喉
甲状腺肿-耳聋综合征	常染色体隐性	SLC26A4	rs111033199	T/T	有害突变纯合	Murray RH， et al. Little evidence to suggest end to physician shortage. 1976Van Hauwe P， et al. Two frequent missense mutations in Pendred syndrome. 1998Coyle B， et al. Molecular analysis of the PDS gene in Pendred syndrome. 1998Campbell C， et al. Pendred syndrome， DFNB4， and PDS/SLC26A4 identification of eight novel mutations and possible genotype-phenotype correlations. 2001Gonzalez Trevino O， et al. Clinical and molecular analysis of three Mexican families with Pendred's syndrome. 2001Pryor SP， et al. SLC26A4/PDS genotype-phenotype correlation in hearing loss with enlargement of the vestibular aqueduct (EVA): evidence that Pendred syndrome and non-syndromic EVA are distinct clinical and genetic entities. 2005Lesnik EA， et al. [Reaction capabilities and structure of poly(rG) and poly(rG)-poly(rC) in solution by the method of the kinetics of hydrogen ion exchange]. 1976Borck G， et al. Mutations in the PDS gene in German families with Pendred's syndrome: V138F is a founder mutation. 2003Prasad S， et al. Pendred syndrome and DFNB4-mutation screening of SLC26A4 by denaturing high-performance liquid chromatography and the identification of eleven novel mutations. 2004Blons H， et al. Screening of SLC26A4 (PDS) gene in Pendred's syndrome: a large spectrum of mutations in France and phenotypic heterogeneity. 2004Napiontek U， et al. Intrafamilial variability of the deafness and goiter phenotype in Pendred syndrome caused by a T416P mutation in the SLC26A4 gene. 2004Yoon JS， et al. Heterogeneity in the processing defect of SLC26A4 mutants. 2008Reardon W， et al. Enlarged vestibular aqueduct: a radiological marker of pendred syndrome， and mutation of the PDS gene. 2000	GENETIC_DISEASE			耳鼻喉
甲状腺肿-耳聋综合征	常染色体隐性	SLC26A4	rs111033244	A/A	正常基因型	Murray RH， et al. Little evidence to suggest end to physician shortage. 1976Van Hauwe P， et al. Two frequent missense mutations in Pendred syndrome. 1998Coyle B， et al. Molecular analysis of the PDS gene in Pendred syndrome. 1998Campbell C， et al. Pendred syndrome， DFNB4， and PDS/SLC26A4 identification of eight novel mutations and possible genotype-phenotype correlations. 2001Gonzalez Trevino O， et al. Clinical and molecular analysis of three Mexican families with Pendred's syndrome. 2001Pryor SP， et al. SLC26A4/PDS genotype-phenotype correlation in hearing loss with enlargement of the vestibular aqueduct (EVA): evidence that Pendred syndrome and non-syndromic EVA are distinct clinical and genetic entities. 2005Lesnik EA， et al. [Reaction capabilities and structure of poly(rG) and poly(rG)-poly(rC) in solution by the method of the kinetics of hydrogen ion exchange]. 1976Borck G， et al. Mutations in the PDS gene in German families with Pendred's syndrome: V138F is a founder mutation. 2003Prasad S， et al. Pendred syndrome and DFNB4-mutation screening of SLC26A4 by denaturing high-performance liquid chromatography and the identification of eleven novel mutations. 2004Blons H， et al. Screening of SLC26A4 (PDS) gene in Pendred's syndrome: a large spectrum of mutations in France and phenotypic heterogeneity. 2004Napiontek U， et al. Intrafamilial variability of the deafness and goiter phenotype in Pendred syndrome caused by a T416P mutation in the SLC26A4 gene. 2004Yoon JS， et al. Heterogeneity in the processing defect of SLC26A4 mutants. 2008Reardon W， et al. Enlarged vestibular aqueduct: a radiological marker of pendred syndrome， and mutation of the PDS gene. 2000	GENETIC_DISEASE			耳鼻喉
甲状腺肿-耳聋综合征	常染色体隐性	SLC26A4	rs111033244	A/G	有害突变携带者	Murray RH， et al. Little evidence to suggest end to physician shortage. 1976Van Hauwe P， et al. Two frequent missense mutations in Pendred syndrome. 1998Coyle B， et al. Molecular analysis of the PDS gene in Pendred syndrome. 1998Campbell C， et al. Pendred syndrome， DFNB4， and PDS/SLC26A4 identification of eight novel mutations and possible genotype-phenotype correlations. 2001Gonzalez Trevino O， et al. Clinical and molecular analysis of three Mexican families with Pendred's syndrome. 2001Pryor SP， et al. SLC26A4/PDS genotype-phenotype correlation in hearing loss with enlargement of the vestibular aqueduct (EVA): evidence that Pendred syndrome and non-syndromic EVA are distinct clinical and genetic entities. 2005Lesnik EA， et al. [Reaction capabilities and structure of poly(rG) and poly(rG)-poly(rC) in solution by the method of the kinetics of hydrogen ion exchange]. 1976Borck G， et al. Mutations in the PDS gene in German families with Pendred's syndrome: V138F is a founder mutation. 2003Prasad S， et al. Pendred syndrome and DFNB4-mutation screening of SLC26A4 by denaturing high-performance liquid chromatography and the identification of eleven novel mutations. 2004Blons H， et al. Screening of SLC26A4 (PDS) gene in Pendred's syndrome: a large spectrum of mutations in France and phenotypic heterogeneity. 2004Napiontek U， et al. Intrafamilial variability of the deafness and goiter phenotype in Pendred syndrome caused by a T416P mutation in the SLC26A4 gene. 2004Yoon JS， et al. Heterogeneity in the processing defect of SLC26A4 mutants. 2008Reardon W， et al. Enlarged vestibular aqueduct: a radiological marker of pendred syndrome， and mutation of the PDS gene. 2000	GENETIC_DISEASE			耳鼻喉
甲状腺肿-耳聋综合征	常染色体隐性	SLC26A4	rs111033244	G/G	有害突变纯合	Murray RH， et al. Little evidence to suggest end to physician shortage. 1976Van Hauwe P， et al. Two frequent missense mutations in Pendred syndrome. 1998Coyle B， et al. Molecular analysis of the PDS gene in Pendred syndrome. 1998Campbell C， et al. Pendred syndrome， DFNB4， and PDS/SLC26A4 identification of eight novel mutations and possible genotype-phenotype correlations. 2001Gonzalez Trevino O， et al. Clinical and molecular analysis of three Mexican families with Pendred's syndrome. 2001Pryor SP， et al. SLC26A4/PDS genotype-phenotype correlation in hearing loss with enlargement of the vestibular aqueduct (EVA): evidence that Pendred syndrome and non-syndromic EVA are distinct clinical and genetic entities. 2005Lesnik EA， et al. [Reaction capabilities and structure of poly(rG) and poly(rG)-poly(rC) in solution by the method of the kinetics of hydrogen ion exchange]. 1976Borck G， et al. Mutations in the PDS gene in German families with Pendred's syndrome: V138F is a founder mutation. 2003Prasad S， et al. Pendred syndrome and DFNB4-mutation screening of SLC26A4 by denaturing high-performance liquid chromatography and the identification of eleven novel mutations. 2004Blons H， et al. Screening of SLC26A4 (PDS) gene in Pendred's syndrome: a large spectrum of mutations in France and phenotypic heterogeneity. 2004Napiontek U， et al. Intrafamilial variability of the deafness and goiter phenotype in Pendred syndrome caused by a T416P mutation in the SLC26A4 gene. 2004Yoon JS， et al. Heterogeneity in the processing defect of SLC26A4 mutants. 2008Reardon W， et al. Enlarged vestibular aqueduct: a radiological marker of pendred syndrome， and mutation of the PDS gene. 2000	GENETIC_DISEASE			耳鼻喉
甲状腺肿-耳聋综合征	常染色体隐性	SLC26A4	rs121908362	A/A	正常基因型	Murray RH， et al. Little evidence to suggest end to physician shortage. 1976Van Hauwe P， et al. Two frequent missense mutations in Pendred syndrome. 1998Coyle B， et al. Molecular analysis of the PDS gene in Pendred syndrome. 1998Campbell C， et al. Pendred syndrome， DFNB4， and PDS/SLC26A4 identification of eight novel mutations and possible genotype-phenotype correlations. 2001Gonzalez Trevino O， et al. Clinical and molecular analysis of three Mexican families with Pendred's syndrome. 2001Pryor SP， et al. SLC26A4/PDS genotype-phenotype correlation in hearing loss with enlargement of the vestibular aqueduct (EVA): evidence that Pendred syndrome and non-syndromic EVA are distinct clinical and genetic entities. 2005Lesnik EA， et al. [Reaction capabilities and structure of poly(rG) and poly(rG)-poly(rC) in solution by the method of the kinetics of hydrogen ion exchange]. 1976Borck G， et al. Mutations in the PDS gene in German families with Pendred's syndrome: V138F is a founder mutation. 2003Prasad S， et al. Pendred syndrome and DFNB4-mutation screening of SLC26A4 by denaturing high-performance liquid chromatography and the identification of eleven novel mutations. 2004Blons H， et al. Screening of SLC26A4 (PDS) gene in Pendred's syndrome: a large spectrum of mutations in France and phenotypic heterogeneity. 2004Napiontek U， et al. Intrafamilial variability of the deafness and goiter phenotype in Pendred syndrome caused by a T416P mutation in the SLC26A4 gene. 2004Yoon JS， et al. Heterogeneity in the processing defect of SLC26A4 mutants. 2008Reardon W， et al. Enlarged vestibular aqueduct: a radiological marker of pendred syndrome， and mutation of the PDS gene. 2000	GENETIC_DISEASE			耳鼻喉
甲状腺肿-耳聋综合征	常染色体隐性	SLC26A4	rs121908362	A/G	有害突变携带者	Murray RH， et al. Little evidence to suggest end to physician shortage. 1976Van Hauwe P， et al. Two frequent missense mutations in Pendred syndrome. 1998Coyle B， et al. Molecular analysis of the PDS gene in Pendred syndrome. 1998Campbell C， et al. Pendred syndrome， DFNB4， and PDS/SLC26A4 identification of eight novel mutations and possible genotype-phenotype correlations. 2001Gonzalez Trevino O， et al. Clinical and molecular analysis of three Mexican families with Pendred's syndrome. 2001Pryor SP， et al. SLC26A4/PDS genotype-phenotype correlation in hearing loss with enlargement of the vestibular aqueduct (EVA): evidence that Pendred syndrome and non-syndromic EVA are distinct clinical and genetic entities. 2005Lesnik EA， et al. [Reaction capabilities and structure of poly(rG) and poly(rG)-poly(rC) in solution by the method of the kinetics of hydrogen ion exchange]. 1976Borck G， et al. Mutations in the PDS gene in German families with Pendred's syndrome: V138F is a founder mutation. 2003Prasad S， et al. Pendred syndrome and DFNB4-mutation screening of SLC26A4 by denaturing high-performance liquid chromatography and the identification of eleven novel mutations. 2004Blons H， et al. Screening of SLC26A4 (PDS) gene in Pendred's syndrome: a large spectrum of mutations in France and phenotypic heterogeneity. 2004Napiontek U， et al. Intrafamilial variability of the deafness and goiter phenotype in Pendred syndrome caused by a T416P mutation in the SLC26A4 gene. 2004Yoon JS， et al. Heterogeneity in the processing defect of SLC26A4 mutants. 2008Reardon W， et al. Enlarged vestibular aqueduct: a radiological marker of pendred syndrome， and mutation of the PDS gene. 2000	GENETIC_DISEASE			耳鼻喉
甲状腺肿-耳聋综合征	常染色体隐性	SLC26A4	rs121908362	G/G	有害突变纯合	Murray RH， et al. Little evidence to suggest end to physician shortage. 1976Van Hauwe P， et al. Two frequent missense mutations in Pendred syndrome. 1998Coyle B， et al. Molecular analysis of the PDS gene in Pendred syndrome. 1998Campbell C， et al. Pendred syndrome， DFNB4， and PDS/SLC26A4 identification of eight novel mutations and possible genotype-phenotype correlations. 2001Gonzalez Trevino O， et al. Clinical and molecular analysis of three Mexican families with Pendred's syndrome. 2001Pryor SP， et al. SLC26A4/PDS genotype-phenotype correlation in hearing loss with enlargement of the vestibular aqueduct (EVA): evidence that Pendred syndrome and non-syndromic EVA are distinct clinical and genetic entities. 2005Lesnik EA， et al. [Reaction capabilities and structure of poly(rG) and poly(rG)-poly(rC) in solution by the method of the kinetics of hydrogen ion exchange]. 1976Borck G， et al. Mutations in the PDS gene in German families with Pendred's syndrome: V138F is a founder mutation. 2003Prasad S， et al. Pendred syndrome and DFNB4-mutation screening of SLC26A4 by denaturing high-performance liquid chromatography and the identification of eleven novel mutations. 2004Blons H， et al. Screening of SLC26A4 (PDS) gene in Pendred's syndrome: a large spectrum of mutations in France and phenotypic heterogeneity. 2004Napiontek U， et al. Intrafamilial variability of the deafness and goiter phenotype in Pendred syndrome caused by a T416P mutation in the SLC26A4 gene. 2004Yoon JS， et al. Heterogeneity in the processing defect of SLC26A4 mutants. 2008Reardon W， et al. Enlarged vestibular aqueduct: a radiological marker of pendred syndrome， and mutation of the PDS gene. 2000	GENETIC_DISEASE			耳鼻喉
甲状腺肿-耳聋综合征	常染色体隐性	SLC26A4	rs28939086	A/A	正常基因型	Murray RH， et al. Little evidence to suggest end to physician shortage. 1976Van Hauwe P， et al. Two frequent missense mutations in Pendred syndrome. 1998Coyle B， et al. Molecular analysis of the PDS gene in Pendred syndrome. 1998Campbell C， et al. Pendred syndrome， DFNB4， and PDS/SLC26A4 identification of eight novel mutations and possible genotype-phenotype correlations. 2001Gonzalez Trevino O， et al. Clinical and molecular analysis of three Mexican families with Pendred's syndrome. 2001Pryor SP， et al. SLC26A4/PDS genotype-phenotype correlation in hearing loss with enlargement of the vestibular aqueduct (EVA): evidence that Pendred syndrome and non-syndromic EVA are distinct clinical and genetic entities. 2005Lesnik EA， et al. [Reaction capabilities and structure of poly(rG) and poly(rG)-poly(rC) in solution by the method of the kinetics of hydrogen ion exchange]. 1976Borck G， et al. Mutations in the PDS gene in German families with Pendred's syndrome: V138F is a founder mutation. 2003Prasad S， et al. Pendred syndrome and DFNB4-mutation screening of SLC26A4 by denaturing high-performance liquid chromatography and the identification of eleven novel mutations. 2004Blons H， et al. Screening of SLC26A4 (PDS) gene in Pendred's syndrome: a large spectrum of mutations in France and phenotypic heterogeneity. 2004Napiontek U， et al. Intrafamilial variability of the deafness and goiter phenotype in Pendred syndrome caused by a T416P mutation in the SLC26A4 gene. 2004Yoon JS， et al. Heterogeneity in the processing defect of SLC26A4 mutants. 2008Reardon W， et al. Enlarged vestibular aqueduct: a radiological marker of pendred syndrome， and mutation of the PDS gene. 2000	GENETIC_DISEASE			耳鼻喉
甲状腺肿-耳聋综合征	常染色体隐性	SLC26A4	rs28939086	A/C	有害突变携带者	Murray RH， et al. Little evidence to suggest end to physician shortage. 1976Van Hauwe P， et al. Two frequent missense mutations in Pendred syndrome. 1998Coyle B， et al. Molecular analysis of the PDS gene in Pendred syndrome. 1998Campbell C， et al. Pendred syndrome， DFNB4， and PDS/SLC26A4 identification of eight novel mutations and possible genotype-phenotype correlations. 2001Gonzalez Trevino O， et al. Clinical and molecular analysis of three Mexican families with Pendred's syndrome. 2001Pryor SP， et al. SLC26A4/PDS genotype-phenotype correlation in hearing loss with enlargement of the vestibular aqueduct (EVA): evidence that Pendred syndrome and non-syndromic EVA are distinct clinical and genetic entities. 2005Lesnik EA， et al. [Reaction capabilities and structure of poly(rG) and poly(rG)-poly(rC) in solution by the method of the kinetics of hydrogen ion exchange]. 1976Borck G， et al. Mutations in the PDS gene in German families with Pendred's syndrome: V138F is a founder mutation. 2003Prasad S， et al. Pendred syndrome and DFNB4-mutation screening of SLC26A4 by denaturing high-performance liquid chromatography and the identification of eleven novel mutations. 2004Blons H， et al. Screening of SLC26A4 (PDS) gene in Pendred's syndrome: a large spectrum of mutations in France and phenotypic heterogeneity. 2004Napiontek U， et al. Intrafamilial variability of the deafness and goiter phenotype in Pendred syndrome caused by a T416P mutation in the SLC26A4 gene. 2004Yoon JS， et al. Heterogeneity in the processing defect of SLC26A4 mutants. 2008Reardon W， et al. Enlarged vestibular aqueduct: a radiological marker of pendred syndrome， and mutation of the PDS gene. 2000	GENETIC_DISEASE			耳鼻喉
甲状腺肿-耳聋综合征	常染色体隐性	SLC26A4	rs28939086	C/C	有害突变纯合	Murray RH， et al. Little evidence to suggest end to physician shortage. 1976Van Hauwe P， et al. Two frequent missense mutations in Pendred syndrome. 1998Coyle B， et al. Molecular analysis of the PDS gene in Pendred syndrome. 1998Campbell C， et al. Pendred syndrome， DFNB4， and PDS/SLC26A4 identification of eight novel mutations and possible genotype-phenotype correlations. 2001Gonzalez Trevino O， et al. Clinical and molecular analysis of three Mexican families with Pendred's syndrome. 2001Pryor SP， et al. SLC26A4/PDS genotype-phenotype correlation in hearing loss with enlargement of the vestibular aqueduct (EVA): evidence that Pendred syndrome and non-syndromic EVA are distinct clinical and genetic entities. 2005Lesnik EA， et al. [Reaction capabilities and structure of poly(rG) and poly(rG)-poly(rC) in solution by the method of the kinetics of hydrogen ion exchange]. 1976Borck G， et al. Mutations in the PDS gene in German families with Pendred's syndrome: V138F is a founder mutation. 2003Prasad S， et al. Pendred syndrome and DFNB4-mutation screening of SLC26A4 by denaturing high-performance liquid chromatography and the identification of eleven novel mutations. 2004Blons H， et al. Screening of SLC26A4 (PDS) gene in Pendred's syndrome: a large spectrum of mutations in France and phenotypic heterogeneity. 2004Napiontek U， et al. Intrafamilial variability of the deafness and goiter phenotype in Pendred syndrome caused by a T416P mutation in the SLC26A4 gene. 2004Yoon JS， et al. Heterogeneity in the processing defect of SLC26A4 mutants. 2008Reardon W， et al. Enlarged vestibular aqueduct: a radiological marker of pendred syndrome， and mutation of the PDS gene. 2000	GENETIC_DISEASE			耳鼻喉
甲状腺肿-耳聋综合征	常染色体隐性	SLC26A4	rs80338848	T/T	正常基因型	Murray RH， et al. Little evidence to suggest end to physician shortage. 1976Van Hauwe P， et al. Two frequent missense mutations in Pendred syndrome. 1998Coyle B， et al. Molecular analysis of the PDS gene in Pendred syndrome. 1998Campbell C， et al. Pendred syndrome， DFNB4， and PDS/SLC26A4 identification of eight novel mutations and possible genotype-phenotype correlations. 2001Gonzalez Trevino O， et al. Clinical and molecular analysis of three Mexican families with Pendred's syndrome. 2001Pryor SP， et al. SLC26A4/PDS genotype-phenotype correlation in hearing loss with enlargement of the vestibular aqueduct (EVA): evidence that Pendred syndrome and non-syndromic EVA are distinct clinical and genetic entities. 2005Lesnik EA， et al. [Reaction capabilities and structure of poly(rG) and poly(rG)-poly(rC) in solution by the method of the kinetics of hydrogen ion exchange]. 1976Borck G， et al. Mutations in the PDS gene in German families with Pendred's syndrome: V138F is a founder mutation. 2003Prasad S， et al. Pendred syndrome and DFNB4-mutation screening of SLC26A4 by denaturing high-performance liquid chromatography and the identification of eleven novel mutations. 2004Blons H， et al. Screening of SLC26A4 (PDS) gene in Pendred's syndrome: a large spectrum of mutations in France and phenotypic heterogeneity. 2004Napiontek U， et al. Intrafamilial variability of the deafness and goiter phenotype in Pendred syndrome caused by a T416P mutation in the SLC26A4 gene. 2004Yoon JS， et al. Heterogeneity in the processing defect of SLC26A4 mutants. 2008Reardon W， et al. Enlarged vestibular aqueduct: a radiological marker of pendred syndrome， and mutation of the PDS gene. 2000	GENETIC_DISEASE			耳鼻喉
甲状腺肿-耳聋综合征	常染色体隐性	SLC26A4	rs80338848	T/C	有害突变携带者	Murray RH， et al. Little evidence to suggest end to physician shortage. 1976Van Hauwe P， et al. Two frequent missense mutations in Pendred syndrome. 1998Coyle B， et al. Molecular analysis of the PDS gene in Pendred syndrome. 1998Campbell C， et al. Pendred syndrome， DFNB4， and PDS/SLC26A4 identification of eight novel mutations and possible genotype-phenotype correlations. 2001Gonzalez Trevino O， et al. Clinical and molecular analysis of three Mexican families with Pendred's syndrome. 2001Pryor SP， et al. SLC26A4/PDS genotype-phenotype correlation in hearing loss with enlargement of the vestibular aqueduct (EVA): evidence that Pendred syndrome and non-syndromic EVA are distinct clinical and genetic entities. 2005Lesnik EA， et al. [Reaction capabilities and structure of poly(rG) and poly(rG)-poly(rC) in solution by the method of the kinetics of hydrogen ion exchange]. 1976Borck G， et al. Mutations in the PDS gene in German families with Pendred's syndrome: V138F is a founder mutation. 2003Prasad S， et al. Pendred syndrome and DFNB4-mutation screening of SLC26A4 by denaturing high-performance liquid chromatography and the identification of eleven novel mutations. 2004Blons H， et al. Screening of SLC26A4 (PDS) gene in Pendred's syndrome: a large spectrum of mutations in France and phenotypic heterogeneity. 2004Napiontek U， et al. Intrafamilial variability of the deafness and goiter phenotype in Pendred syndrome caused by a T416P mutation in the SLC26A4 gene. 2004Yoon JS， et al. Heterogeneity in the processing defect of SLC26A4 mutants. 2008Reardon W， et al. Enlarged vestibular aqueduct: a radiological marker of pendred syndrome， and mutation of the PDS gene. 2000	GENETIC_DISEASE			耳鼻喉
甲状腺肿-耳聋综合征	常染色体隐性	SLC26A4	rs80338848	C/C	有害突变纯合	Murray RH， et al. Little evidence to suggest end to physician shortage. 1976Van Hauwe P， et al. Two frequent missense mutations in Pendred syndrome. 1998Coyle B， et al. Molecular analysis of the PDS gene in Pendred syndrome. 1998Campbell C， et al. Pendred syndrome， DFNB4， and PDS/SLC26A4 identification of eight novel mutations and possible genotype-phenotype correlations. 2001Gonzalez Trevino O， et al. Clinical and molecular analysis of three Mexican families with Pendred's syndrome. 2001Pryor SP， et al. SLC26A4/PDS genotype-phenotype correlation in hearing loss with enlargement of the vestibular aqueduct (EVA): evidence that Pendred syndrome and non-syndromic EVA are distinct clinical and genetic entities. 2005Lesnik EA， et al. [Reaction capabilities and structure of poly(rG) and poly(rG)-poly(rC) in solution by the method of the kinetics of hydrogen ion exchange]. 1976Borck G， et al. Mutations in the PDS gene in German families with Pendred's syndrome: V138F is a founder mutation. 2003Prasad S， et al. Pendred syndrome and DFNB4-mutation screening of SLC26A4 by denaturing high-performance liquid chromatography and the identification of eleven novel mutations. 2004Blons H， et al. Screening of SLC26A4 (PDS) gene in Pendred's syndrome: a large spectrum of mutations in France and phenotypic heterogeneity. 2004Napiontek U， et al. Intrafamilial variability of the deafness and goiter phenotype in Pendred syndrome caused by a T416P mutation in the SLC26A4 gene. 2004Yoon JS， et al. Heterogeneity in the processing defect of SLC26A4 mutants. 2008Reardon W， et al. Enlarged vestibular aqueduct: a radiological marker of pendred syndrome， and mutation of the PDS gene. 2000	GENETIC_DISEASE			耳鼻喉
A型尼曼-匹克病	常染色体隐性	SMPD1	rs120074117	G/G	正常基因型		GENETIC_DISEASE			遗传代谢
A型尼曼-匹克病	常染色体隐性	SMPD1	rs120074117	G/T	有害突变携带者		GENETIC_DISEASE			遗传代谢
A型尼曼-匹克病	常染色体隐性	SMPD1	rs120074117	T/T	有害突变纯合		GENETIC_DISEASE			遗传代谢
A型尼曼-匹克病	常染色体隐性	SMPD1	rs120074124	T/T	正常基因型		GENETIC_DISEASE			遗传代谢
A型尼曼-匹克病	常染色体隐性	SMPD1	rs120074124	T/C	有害突变携带者		GENETIC_DISEASE			遗传代谢
A型尼曼-匹克病	常染色体隐性	SMPD1	rs120074124	C/C	有害突变纯合		GENETIC_DISEASE			遗传代谢
神经元蜡样质脂褐质沉积症	常染色体隐性	PPT1	rs137852696	T/T	正常基因型	Holmberg V， et al. Phenotype-genotype correlation in eight patients with Finnish variant late infantile NCL (CLN5). 2000	GENETIC_DISEASE			神经系统
神经元蜡样质脂褐质沉积症	常染色体隐性	PPT1	rs137852696	T/G	有害突变携带者	Holmberg V， et al. Phenotype-genotype correlation in eight patients with Finnish variant late infantile NCL (CLN5). 2000	GENETIC_DISEASE			神经系统
神经元蜡样质脂褐质沉积症	常染色体隐性	PPT1	rs137852696	G/G	有害突变纯合	Holmberg V， et al. Phenotype-genotype correlation in eight patients with Finnish variant late infantile NCL (CLN5). 2000	GENETIC_DISEASE			神经系统
神经元蜡样质脂褐质沉积症	常染色体隐性	PPT1	rs137852700	G/G	正常基因型	Holmberg V， et al. Phenotype-genotype correlation in eight patients with Finnish variant late infantile NCL (CLN5). 2000	GENETIC_DISEASE			神经系统
神经元蜡样质脂褐质沉积症	常染色体隐性	PPT1	rs137852700	G/A	有害突变携带者	Holmberg V， et al. Phenotype-genotype correlation in eight patients with Finnish variant late infantile NCL (CLN5). 2000	GENETIC_DISEASE			神经系统
神经元蜡样质脂褐质沉积症	常染色体隐性	PPT1	rs137852700	A/A	有害突变纯合	Holmberg V， et al. Phenotype-genotype correlation in eight patients with Finnish variant late infantile NCL (CLN5). 2000	GENETIC_DISEASE			神经系统
中链酰基辅酶A脱氢酶缺乏症	常染色体隐性	ACADM	rs373715782	C/C	正常基因型		GENETIC_DISEASE			遗传代谢
中链酰基辅酶A脱氢酶缺乏症	常染色体隐性	ACADM	rs373715782	C/T	有害突变携带者		GENETIC_DISEASE			遗传代谢
中链酰基辅酶A脱氢酶缺乏症	常染色体隐性	ACADM	rs373715782	T/T	有害突变纯合		GENETIC_DISEASE			遗传代谢
中链酰基辅酶A脱氢酶缺乏症	常染色体隐性	ACADM	rs77931234	A/A	正常基因型		GENETIC_DISEASE			遗传代谢
中链酰基辅酶A脱氢酶缺乏症	常染色体隐性	ACADM	rs77931234	A/G	有害突变携带者		GENETIC_DISEASE			遗传代谢
中链酰基辅酶A脱氢酶缺乏症	常染色体隐性	ACADM	rs77931234	G/G	有害突变纯合		GENETIC_DISEASE			遗传代谢
脑肝肾综合征	常染色体隐性	PEX1	rs61750420	C/C	正常基因型		GENETIC_DISEASE			其他
脑肝肾综合征	常染色体隐性	PEX1	rs61750420	C/T	有害突变携带者		GENETIC_DISEASE			其他
脑肝肾综合征	常染色体隐性	PEX1	rs61750420	T/T	有害突变纯合		GENETIC_DISEASE			其他
高雪氏症	常染色体隐性遗传病	GBA	rs387906315	-/-	正常基因型	Kolodny EH， et al. Mutation analysis of an Ashkenazi Jewish family with Gaucher disease in three successive generations. 1990Firon N， et al. Genotype assignment in Gaucher disease by selective amplification of the active glucocerebrosidase gene. 1990Ida H， et al. Characteristics of gene mutations among 32 unrelated Japanese Gaucher disease patients: absence of the common Jewish 84GG and 1226G mutations. 1995Beutler E， et al. Identification of six new Gaucher disease mutations. 1993Grabowski GA， et al. Gaucher's disease: molecular， genetic and enzymological aspects. 1997Cormand B， et al. Molecular analysis and clinical findings in the Spanish Gaucher disease population: putative haplotype of the N370S ancestral chromosome. 2015Latham T， et al. Complex alleles of the acid beta-glucosidase gene in Gaucher disease. 1990Theophilus BD， et al. Comparison of RNase A， a chemical cleavage and GC-clamped denaturing gradient gel electrophoresis for the detection of mutations in exon 9 of the human acid beta-glucosidase gene. 1989	GENETIC_DISEASE			遗传代谢
高雪氏症	常染色体隐性遗传病	GBA	rs387906315	-/C	有害突变携带者	Kolodny EH， et al. Mutation analysis of an Ashkenazi Jewish family with Gaucher disease in three successive generations. 1990Firon N， et al. Genotype assignment in Gaucher disease by selective amplification of the active glucocerebrosidase gene. 1990Ida H， et al. Characteristics of gene mutations among 32 unrelated Japanese Gaucher disease patients: absence of the common Jewish 84GG and 1226G mutations. 1995Beutler E， et al. Identification of six new Gaucher disease mutations. 1993Grabowski GA， et al. Gaucher's disease: molecular， genetic and enzymological aspects. 1997Cormand B， et al. Molecular analysis and clinical findings in the Spanish Gaucher disease population: putative haplotype of the N370S ancestral chromosome. 2015Latham T， et al. Complex alleles of the acid beta-glucosidase gene in Gaucher disease. 1990Theophilus BD， et al. Comparison of RNase A， a chemical cleavage and GC-clamped denaturing gradient gel electrophoresis for the detection of mutations in exon 9 of the human acid beta-glucosidase gene. 1989	GENETIC_DISEASE			遗传代谢
高雪氏症	常染色体隐性遗传病	GBA	rs387906315	C/C	有害突变纯合	Kolodny EH， et al. Mutation analysis of an Ashkenazi Jewish family with Gaucher disease in three successive generations. 1990Firon N， et al. Genotype assignment in Gaucher disease by selective amplification of the active glucocerebrosidase gene. 1990Ida H， et al. Characteristics of gene mutations among 32 unrelated Japanese Gaucher disease patients: absence of the common Jewish 84GG and 1226G mutations. 1995Beutler E， et al. Identification of six new Gaucher disease mutations. 1993Grabowski GA， et al. Gaucher's disease: molecular， genetic and enzymological aspects. 1997Cormand B， et al. Molecular analysis and clinical findings in the Spanish Gaucher disease population: putative haplotype of the N370S ancestral chromosome. 2015Latham T， et al. Complex alleles of the acid beta-glucosidase gene in Gaucher disease. 1990Theophilus BD， et al. Comparison of RNase A， a chemical cleavage and GC-clamped denaturing gradient gel electrophoresis for the detection of mutations in exon 9 of the human acid beta-glucosidase gene. 1989	GENETIC_DISEASE			遗传代谢
高雪氏症	常染色体隐性遗传病	GBA	rs80356769	C/C	正常基因型	Kolodny EH， et al. Mutation analysis of an Ashkenazi Jewish family with Gaucher disease in three successive generations. 1990Firon N， et al. Genotype assignment in Gaucher disease by selective amplification of the active glucocerebrosidase gene. 1990Ida H， et al. Characteristics of gene mutations among 32 unrelated Japanese Gaucher disease patients: absence of the common Jewish 84GG and 1226G mutations. 1995Beutler E， et al. Identification of six new Gaucher disease mutations. 1993Grabowski GA， et al. Gaucher's disease: molecular， genetic and enzymological aspects. 1997Cormand B， et al. Molecular analysis and clinical findings in the Spanish Gaucher disease population: putative haplotype of the N370S ancestral chromosome. 2015Latham T， et al. Complex alleles of the acid beta-glucosidase gene in Gaucher disease. 1990Theophilus BD， et al. Comparison of RNase A， a chemical cleavage and GC-clamped denaturing gradient gel electrophoresis for the detection of mutations in exon 9 of the human acid beta-glucosidase gene. 1989	GENETIC_DISEASE			遗传代谢
高雪氏症	常染色体隐性遗传病	GBA	rs80356769	C/A	有害突变携带者	Kolodny EH， et al. Mutation analysis of an Ashkenazi Jewish family with Gaucher disease in three successive generations. 1990Firon N， et al. Genotype assignment in Gaucher disease by selective amplification of the active glucocerebrosidase gene. 1990Ida H， et al. Characteristics of gene mutations among 32 unrelated Japanese Gaucher disease patients: absence of the common Jewish 84GG and 1226G mutations. 1995Beutler E， et al. Identification of six new Gaucher disease mutations. 1993Grabowski GA， et al. Gaucher's disease: molecular， genetic and enzymological aspects. 1997Cormand B， et al. Molecular analysis and clinical findings in the Spanish Gaucher disease population: putative haplotype of the N370S ancestral chromosome. 2015Latham T， et al. Complex alleles of the acid beta-glucosidase gene in Gaucher disease. 1990Theophilus BD， et al. Comparison of RNase A， a chemical cleavage and GC-clamped denaturing gradient gel electrophoresis for the detection of mutations in exon 9 of the human acid beta-glucosidase gene. 1989	GENETIC_DISEASE			遗传代谢
高雪氏症	常染色体隐性遗传病	GBA	rs80356769	A/A	有害突变纯合	Kolodny EH， et al. Mutation analysis of an Ashkenazi Jewish family with Gaucher disease in three successive generations. 1990Firon N， et al. Genotype assignment in Gaucher disease by selective amplification of the active glucocerebrosidase gene. 1990Ida H， et al. Characteristics of gene mutations among 32 unrelated Japanese Gaucher disease patients: absence of the common Jewish 84GG and 1226G mutations. 1995Beutler E， et al. Identification of six new Gaucher disease mutations. 1993Grabowski GA， et al. Gaucher's disease: molecular， genetic and enzymological aspects. 1997Cormand B， et al. Molecular analysis and clinical findings in the Spanish Gaucher disease population: putative haplotype of the N370S ancestral chromosome. 2015Latham T， et al. Complex alleles of the acid beta-glucosidase gene in Gaucher disease. 1990Theophilus BD， et al. Comparison of RNase A， a chemical cleavage and GC-clamped denaturing gradient gel electrophoresis for the detection of mutations in exon 9 of the human acid beta-glucosidase gene. 1989	GENETIC_DISEASE			遗传代谢
高雪氏症	常染色体隐性遗传病	GBA	rs76763715	T/T	正常基因型	Kolodny EH， et al. Mutation analysis of an Ashkenazi Jewish family with Gaucher disease in three successive generations. 1990Firon N， et al. Genotype assignment in Gaucher disease by selective amplification of the active glucocerebrosidase gene. 1990Ida H， et al. Characteristics of gene mutations among 32 unrelated Japanese Gaucher disease patients: absence of the common Jewish 84GG and 1226G mutations. 1995Beutler E， et al. Identification of six new Gaucher disease mutations. 1993Grabowski GA， et al. Gaucher's disease: molecular， genetic and enzymological aspects. 1997Cormand B， et al. Molecular analysis and clinical findings in the Spanish Gaucher disease population: putative haplotype of the N370S ancestral chromosome. 2015Latham T， et al. Complex alleles of the acid beta-glucosidase gene in Gaucher disease. 1990Theophilus BD， et al. Comparison of RNase A， a chemical cleavage and GC-clamped denaturing gradient gel electrophoresis for the detection of mutations in exon 9 of the human acid beta-glucosidase gene. 1989	GENETIC_DISEASE			遗传代谢
高雪氏症	常染色体隐性遗传病	GBA	rs76763715	T/C	有害突变携带者	Kolodny EH， et al. Mutation analysis of an Ashkenazi Jewish family with Gaucher disease in three successive generations. 1990Firon N， et al. Genotype assignment in Gaucher disease by selective amplification of the active glucocerebrosidase gene. 1990Ida H， et al. Characteristics of gene mutations among 32 unrelated Japanese Gaucher disease patients: absence of the common Jewish 84GG and 1226G mutations. 1995Beutler E， et al. Identification of six new Gaucher disease mutations. 1993Grabowski GA， et al. Gaucher's disease: molecular， genetic and enzymological aspects. 1997Cormand B， et al. Molecular analysis and clinical findings in the Spanish Gaucher disease population: putative haplotype of the N370S ancestral chromosome. 2015Latham T， et al. Complex alleles of the acid beta-glucosidase gene in Gaucher disease. 1990Theophilus BD， et al. Comparison of RNase A， a chemical cleavage and GC-clamped denaturing gradient gel electrophoresis for the detection of mutations in exon 9 of the human acid beta-glucosidase gene. 1989	GENETIC_DISEASE			遗传代谢
高雪氏症	常染色体隐性遗传病	GBA	rs76763715	C/C	有害突变纯合	Kolodny EH， et al. Mutation analysis of an Ashkenazi Jewish family with Gaucher disease in three successive generations. 1990Firon N， et al. Genotype assignment in Gaucher disease by selective amplification of the active glucocerebrosidase gene. 1990Ida H， et al. Characteristics of gene mutations among 32 unrelated Japanese Gaucher disease patients: absence of the common Jewish 84GG and 1226G mutations. 1995Beutler E， et al. Identification of six new Gaucher disease mutations. 1993Grabowski GA， et al. Gaucher's disease: molecular， genetic and enzymological aspects. 1997Cormand B， et al. Molecular analysis and clinical findings in the Spanish Gaucher disease population: putative haplotype of the N370S ancestral chromosome. 2015Latham T， et al. Complex alleles of the acid beta-glucosidase gene in Gaucher disease. 1990Theophilus BD， et al. Comparison of RNase A， a chemical cleavage and GC-clamped denaturing gradient gel electrophoresis for the detection of mutations in exon 9 of the human acid beta-glucosidase gene. 1989	GENETIC_DISEASE			遗传代谢
GRACILE综合征		BCS1L	rs28937590	A/A	正常基因型		GENETIC_DISEASE			其他
GRACILE综合征		BCS1L	rs28937590	A/G	有害突变携带者		GENETIC_DISEASE			其他
GRACILE综合征		BCS1L	rs28937590	G/G	有害突变纯合		GENETIC_DISEASE			其他
范可尼贫血	常染色体隐性	FANCC	rs104886457	G/G	正常基因型		GENETIC_DISEASE			血液系统
范可尼贫血	常染色体隐性	FANCC	rs104886457	G/A	有害突变携带者		GENETIC_DISEASE			血液系统
范可尼贫血	常染色体隐性	FANCC	rs104886457	AA	有害突变纯合		GENETIC_DISEASE			血液系统
范可尼贫血	常染色体隐性	FANCC	rs104886459	CC	正常基因型		GENETIC_DISEASE			血液系统
范可尼贫血	常染色体隐性	FANCC	rs104886459	-/C	有害突变携带者		GENETIC_DISEASE			血液系统
范可尼贫血	常染色体隐性	FANCC	rs104886459	-/-	有害突变纯合		GENETIC_DISEASE			血液系统
B型家族性高胆固醇血症	常染色体显性	APOB	rs12713559	G/G	正常基因型	Sun XM， et al. Characterization of a splice-site mutation in the gene for the LDL receptor associated with an unpredictably severe clinical phenotype in English patients with heterozygous FH. 1995Biesecker LG， et al. The ClinSeq Project: piloting large-scale genome sequencing for research in genomic medicine. 2009	GENETIC_DISEASE			血液系统
B型家族性高胆固醇血症	常染色体显性	APOB	rs12713559	G/A	有害突变携带者	Sun XM， et al. Characterization of a splice-site mutation in the gene for the LDL receptor associated with an unpredictably severe clinical phenotype in English patients with heterozygous FH. 1995Biesecker LG， et al. The ClinSeq Project: piloting large-scale genome sequencing for research in genomic medicine. 2009	GENETIC_DISEASE			血液系统
B型家族性高胆固醇血症	常染色体显性	APOB	rs12713559	A/A	有害突变纯合	Sun XM， et al. Characterization of a splice-site mutation in the gene for the LDL receptor associated with an unpredictably severe clinical phenotype in English patients with heterozygous FH. 1995Biesecker LG， et al. The ClinSeq Project: piloting large-scale genome sequencing for research in genomic medicine. 2009	GENETIC_DISEASE			血液系统
B型家族性高胆固醇血症	常染色体显性	APOB	rs144467873	G/G	正常基因型	Sun XM， et al. Characterization of a splice-site mutation in the gene for the LDL receptor associated with an unpredictably severe clinical phenotype in English patients with heterozygous FH. 1995Biesecker LG， et al. The ClinSeq Project: piloting large-scale genome sequencing for research in genomic medicine. 2009	GENETIC_DISEASE			血液系统
B型家族性高胆固醇血症	常染色体显性	APOB	rs144467873	G/A	有害突变携带者	Sun XM， et al. Characterization of a splice-site mutation in the gene for the LDL receptor associated with an unpredictably severe clinical phenotype in English patients with heterozygous FH. 1995Biesecker LG， et al. The ClinSeq Project: piloting large-scale genome sequencing for research in genomic medicine. 2009	GENETIC_DISEASE			血液系统
B型家族性高胆固醇血症	常染色体显性	APOB	rs144467873	A/A	有害突变纯合	Sun XM， et al. Characterization of a splice-site mutation in the gene for the LDL receptor associated with an unpredictably severe clinical phenotype in English patients with heterozygous FH. 1995Biesecker LG， et al. The ClinSeq Project: piloting large-scale genome sequencing for research in genomic medicine. 2009	GENETIC_DISEASE			血液系统
B型家族性高胆固醇血症	常染色体显性		rs112029328	G/G	正常基因型	Sun XM， et al. Characterization of a splice-site mutation in the gene for the LDL receptor associated with an unpredictably severe clinical phenotype in English patients with heterozygous FH. 1995Biesecker LG， et al. The ClinSeq Project: piloting large-scale genome sequencing for research in genomic medicine. 2009	GENETIC_DISEASE			血液系统
B型家族性高胆固醇血症	常染色体显性		rs112029328	A/A	有害突变纯合	Sun XM， et al. Characterization of a splice-site mutation in the gene for the LDL receptor associated with an unpredictably severe clinical phenotype in English patients with heterozygous FH. 1995Biesecker LG， et al. The ClinSeq Project: piloting large-scale genome sequencing for research in genomic medicine. 2009	GENETIC_DISEASE			血液系统
B型家族性高胆固醇血症	常染色体显性		rs112029328	G/T	有害突变携带者	Sun XM， et al. Characterization of a splice-site mutation in the gene for the LDL receptor associated with an unpredictably severe clinical phenotype in English patients with heterozygous FH. 1995Biesecker LG， et al. The ClinSeq Project: piloting large-scale genome sequencing for research in genomic medicine. 2009	GENETIC_DISEASE			血液系统
B型家族性高胆固醇血症	常染色体显性		rs112029328	G/A	有害突变携带者	Sun XM， et al. Characterization of a splice-site mutation in the gene for the LDL receptor associated with an unpredictably severe clinical phenotype in English patients with heterozygous FH. 1995Biesecker LG， et al. The ClinSeq Project: piloting large-scale genome sequencing for research in genomic medicine. 2009	GENETIC_DISEASE			血液系统
B型家族性高胆固醇血症	常染色体显性		rs112029328	A/A	有害突变纯合	Sun XM， et al. Characterization of a splice-site mutation in the gene for the LDL receptor associated with an unpredictably severe clinical phenotype in English patients with heterozygous FH. 1995Biesecker LG， et al. The ClinSeq Project: piloting large-scale genome sequencing for research in genomic medicine. 2009	GENETIC_DISEASE			血液系统
遗传性果糖不能耐受症	常染色体隐性	ALDOB	rs1800546	C/C	正常基因型	CLINICAL OVERVIEW:[edit]RISK-ASSOCIATED SNP:[edit]Cross NC， et al. Catalytic deficiency of human aldolase B in hereditary fructose intolerance caused by a common missense mutation. 1988Esposito G， et al. Six novel alleles identified in Italian hereditary fructose intolerance patients enlarge the mutation spectrum of the aldolase B gene. 2004Davit-Spraul A， et al. Hereditary fructose intolerance: frequency and spectrum mutations of the aldolase B gene in a large patients cohort from France--identification of eight new mutations. 2008Malay AD， et al. Structure of the thermolabile mutant aldolase B， A149P: molecular basis of hereditary fructose intolerance. 2005Wenzel JJ， et al. Chronic diarrhea in a 5-year-old girl: pitfall in routine laboratory testing with potentially severe consequences. 2009Cross NC， et al. Molecular analysis of aldolase B genes in hereditary fructose intolerance. 1990	GENETIC_DISEASE			遗传代谢
遗传性果糖不能耐受症	常染色体隐性	ALDOB	rs1800546	C/G	有害突变携带者	CLINICAL OVERVIEW:[edit]RISK-ASSOCIATED SNP:[edit]Cross NC， et al. Catalytic deficiency of human aldolase B in hereditary fructose intolerance caused by a common missense mutation. 1988Esposito G， et al. Six novel alleles identified in Italian hereditary fructose intolerance patients enlarge the mutation spectrum of the aldolase B gene. 2004Davit-Spraul A， et al. Hereditary fructose intolerance: frequency and spectrum mutations of the aldolase B gene in a large patients cohort from France--identification of eight new mutations. 2008Malay AD， et al. Structure of the thermolabile mutant aldolase B， A149P: molecular basis of hereditary fructose intolerance. 2005Wenzel JJ， et al. Chronic diarrhea in a 5-year-old girl: pitfall in routine laboratory testing with potentially severe consequences. 2009Cross NC， et al. Molecular analysis of aldolase B genes in hereditary fructose intolerance. 1990	GENETIC_DISEASE			遗传代谢
遗传性果糖不能耐受症	常染色体隐性	ALDOB	rs1800546	G/G	有害突变纯合	CLINICAL OVERVIEW:[edit]RISK-ASSOCIATED SNP:[edit]Cross NC， et al. Catalytic deficiency of human aldolase B in hereditary fructose intolerance caused by a common missense mutation. 1988Esposito G， et al. Six novel alleles identified in Italian hereditary fructose intolerance patients enlarge the mutation spectrum of the aldolase B gene. 2004Davit-Spraul A， et al. Hereditary fructose intolerance: frequency and spectrum mutations of the aldolase B gene in a large patients cohort from France--identification of eight new mutations. 2008Malay AD， et al. Structure of the thermolabile mutant aldolase B， A149P: molecular basis of hereditary fructose intolerance. 2005Wenzel JJ， et al. Chronic diarrhea in a 5-year-old girl: pitfall in routine laboratory testing with potentially severe consequences. 2009Cross NC， et al. Molecular analysis of aldolase B genes in hereditary fructose intolerance. 1990	GENETIC_DISEASE			遗传代谢
遗传性果糖不能耐受症	常染色体隐性	ALDOB	rs387906225	GTTT/GTTT	正常基因型	CLINICAL OVERVIEW:[edit]RISK-ASSOCIATED SNP:[edit]Cross NC， et al. Catalytic deficiency of human aldolase B in hereditary fructose intolerance caused by a common missense mutation. 1988Esposito G， et al. Six novel alleles identified in Italian hereditary fructose intolerance patients enlarge the mutation spectrum of the aldolase B gene. 2004Davit-Spraul A， et al. Hereditary fructose intolerance: frequency and spectrum mutations of the aldolase B gene in a large patients cohort from France--identification of eight new mutations. 2008Malay AD， et al. Structure of the thermolabile mutant aldolase B， A149P: molecular basis of hereditary fructose intolerance. 2005Wenzel JJ， et al. Chronic diarrhea in a 5-year-old girl: pitfall in routine laboratory testing with potentially severe consequences. 2009Cross NC， et al. Molecular analysis of aldolase B genes in hereditary fructose intolerance. 1990	GENETIC_DISEASE			遗传代谢
遗传性果糖不能耐受症	常染色体隐性	ALDOB	rs387906225	GTTT/-	有害突变携带者	CLINICAL OVERVIEW:[edit]RISK-ASSOCIATED SNP:[edit]Cross NC， et al. Catalytic deficiency of human aldolase B in hereditary fructose intolerance caused by a common missense mutation. 1988Esposito G， et al. Six novel alleles identified in Italian hereditary fructose intolerance patients enlarge the mutation spectrum of the aldolase B gene. 2004Davit-Spraul A， et al. Hereditary fructose intolerance: frequency and spectrum mutations of the aldolase B gene in a large patients cohort from France--identification of eight new mutations. 2008Malay AD， et al. Structure of the thermolabile mutant aldolase B， A149P: molecular basis of hereditary fructose intolerance. 2005Wenzel JJ， et al. Chronic diarrhea in a 5-year-old girl: pitfall in routine laboratory testing with potentially severe consequences. 2009Cross NC， et al. Molecular analysis of aldolase B genes in hereditary fructose intolerance. 1990	GENETIC_DISEASE			遗传代谢
遗传性果糖不能耐受症	常染色体隐性	ALDOB	rs387906225	-/-	有害突变纯合	CLINICAL OVERVIEW:[edit]RISK-ASSOCIATED SNP:[edit]Cross NC， et al. Catalytic deficiency of human aldolase B in hereditary fructose intolerance caused by a common missense mutation. 1988Esposito G， et al. Six novel alleles identified in Italian hereditary fructose intolerance patients enlarge the mutation spectrum of the aldolase B gene. 2004Davit-Spraul A， et al. Hereditary fructose intolerance: frequency and spectrum mutations of the aldolase B gene in a large patients cohort from France--identification of eight new mutations. 2008Malay AD， et al. Structure of the thermolabile mutant aldolase B， A149P: molecular basis of hereditary fructose intolerance. 2005Wenzel JJ， et al. Chronic diarrhea in a 5-year-old girl: pitfall in routine laboratory testing with potentially severe consequences. 2009Cross NC， et al. Molecular analysis of aldolase B genes in hereditary fructose intolerance. 1990	GENETIC_DISEASE			遗传代谢
遗传性果糖不能耐受症	常染色体隐性	ALDOB	rs78340951	G/G	正常基因型	CLINICAL OVERVIEW:[edit]RISK-ASSOCIATED SNP:[edit]Cross NC， et al. Catalytic deficiency of human aldolase B in hereditary fructose intolerance caused by a common missense mutation. 1988Esposito G， et al. Six novel alleles identified in Italian hereditary fructose intolerance patients enlarge the mutation spectrum of the aldolase B gene. 2004Davit-Spraul A， et al. Hereditary fructose intolerance: frequency and spectrum mutations of the aldolase B gene in a large patients cohort from France--identification of eight new mutations. 2008Malay AD， et al. Structure of the thermolabile mutant aldolase B， A149P: molecular basis of hereditary fructose intolerance. 2005Wenzel JJ， et al. Chronic diarrhea in a 5-year-old girl: pitfall in routine laboratory testing with potentially severe consequences. 2009Cross NC， et al. Molecular analysis of aldolase B genes in hereditary fructose intolerance. 1990	GENETIC_DISEASE			遗传代谢
遗传性果糖不能耐受症	常染色体隐性	ALDOB	rs78340951	G/C	有害突变携带者	CLINICAL OVERVIEW:[edit]RISK-ASSOCIATED SNP:[edit]Cross NC， et al. Catalytic deficiency of human aldolase B in hereditary fructose intolerance caused by a common missense mutation. 1988Esposito G， et al. Six novel alleles identified in Italian hereditary fructose intolerance patients enlarge the mutation spectrum of the aldolase B gene. 2004Davit-Spraul A， et al. Hereditary fructose intolerance: frequency and spectrum mutations of the aldolase B gene in a large patients cohort from France--identification of eight new mutations. 2008Malay AD， et al. Structure of the thermolabile mutant aldolase B， A149P: molecular basis of hereditary fructose intolerance. 2005Wenzel JJ， et al. Chronic diarrhea in a 5-year-old girl: pitfall in routine laboratory testing with potentially severe consequences. 2009Cross NC， et al. Molecular analysis of aldolase B genes in hereditary fructose intolerance. 1990	GENETIC_DISEASE			遗传代谢
遗传性果糖不能耐受症	常染色体隐性	ALDOB	rs78340951	C/C	有害突变纯合	CLINICAL OVERVIEW:[edit]RISK-ASSOCIATED SNP:[edit]Cross NC， et al. Catalytic deficiency of human aldolase B in hereditary fructose intolerance caused by a common missense mutation. 1988Esposito G， et al. Six novel alleles identified in Italian hereditary fructose intolerance patients enlarge the mutation spectrum of the aldolase B gene. 2004Davit-Spraul A， et al. Hereditary fructose intolerance: frequency and spectrum mutations of the aldolase B gene in a large patients cohort from France--identification of eight new mutations. 2008Malay AD， et al. Structure of the thermolabile mutant aldolase B， A149P: molecular basis of hereditary fructose intolerance. 2005Wenzel JJ， et al. Chronic diarrhea in a 5-year-old girl: pitfall in routine laboratory testing with potentially severe consequences. 2009Cross NC， et al. Molecular analysis of aldolase B genes in hereditary fructose intolerance. 1990	GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs5030859	C/C	正常基因型		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs5030859	C/T	有害突变携带者		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs5030859	T/T	有害突变纯合		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs5030860	T/T	正常基因型		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs5030860	C/T	有害突变携带者		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs5030860	C/C	有害突变纯合		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs62514952	C/C	正常基因型		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs62514952	A/C	有害突变携带者		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs62514952	A/A	有害突变纯合		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs62516092	G/G	正常基因型		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs62516092	C/G	有害突变携带者		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs62516092	C/C	有害突变纯合		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs62642932	C/C	正常基因型		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs62642932	C/T	有害突变携带者		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs62642932	T/T	有害突变纯合		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs62642933	A/A	正常基因型		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs62642933	A/C	有害突变携带者		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs62642933	C/C	有害突变纯合		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs5030849	C/C	正常基因型		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs5030849	C/T	有害突变携带者		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs5030849	T/T	有害突变纯合		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs62508588	C/C	正常基因型		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs62508588	C/T	有害突变携带者		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs62508588	T/T	有害突变纯合		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs5030843	C/C	正常基因型		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs5030843	C/T	有害突变携带者		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs5030843	T/T	有害突变纯合		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs5030847	G/G	正常基因型		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs5030847	G/C	有害突变携带者		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs5030847	G/A	有害突变携带者		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs5030847	A/A	有害突变纯合		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs5030850	G/G	正常基因型		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs5030850	G/A	有害突变携带者		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs5030850	A/A	有害突变纯合		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs75193786	A/A	正常基因型		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs75193786	A/G	有害突变携带者		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs75193786	G/G	有害突变纯合		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs118203925	G/G	正常基因型		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs118203925	A/G	有害突变携带者		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs118203925	A/A	有害突变纯合		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs62516095	G/G	正常基因型		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs62516095	C/G	有害突变携带者		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs62516095	C/C	有害突变纯合		GENETIC_DISEASE			遗传代谢
苯丙酮尿症	常染色体隐性	PAH	rs62516095	G/T	有害突变携带者		GENETIC_DISEASE			遗传代谢
胼胝体伴周围神经发育不全	常染色体隐性	SLC12A6	rs121908428	G/G	正常基因型		GENETIC_DISEASE			神经系统
胼胝体伴周围神经发育不全	常染色体隐性	SLC12A6	rs121908428	G/A	有害突变携带者		GENETIC_DISEASE			神经系统
胼胝体伴周围神经发育不全	常染色体隐性	SLC12A6	rs121908428	A/A	有害突变纯合		GENETIC_DISEASE			神经系统
肝糖原贮积症Ib型	常染色体隐性	SLC37A4	rs80356491	AG/AG	正常基因型	Veiga-da-Cunha M， et al. A gene on chromosome 11q23 coding for a putative glucose- 6-phosphate translocase is mutated in glycogen-storage disease types Ib and Ic. 1998Janecke AR， et al. Molecular diagnosis of type 1c glycogen storage disease. 1999	GENETIC_DISEASE			遗传代谢
肝糖原贮积症Ib型	常染色体隐性	SLC37A4	rs80356491	AG/-	有害突变携带者	Veiga-da-Cunha M， et al. A gene on chromosome 11q23 coding for a putative glucose- 6-phosphate translocase is mutated in glycogen-storage disease types Ib and Ic. 1998Janecke AR， et al. Molecular diagnosis of type 1c glycogen storage disease. 1999	GENETIC_DISEASE			遗传代谢
肝糖原贮积症Ib型	常染色体隐性	SLC37A4	rs80356491	-/-	有害突变纯合	Veiga-da-Cunha M， et al. A gene on chromosome 11q23 coding for a putative glucose- 6-phosphate translocase is mutated in glycogen-storage disease types Ib and Ic. 1998Janecke AR， et al. Molecular diagnosis of type 1c glycogen storage disease. 1999	GENETIC_DISEASE			遗传代谢
聚乙二醇干扰素α-2a、聚乙二醇干扰素α-2b和利巴韦林		IFNL4	rs12979860	C/C		Muir A J， Gong L， Johnson S G， et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon‐α–Based Regimens[J]. Clinical Pharmacology & Therapeutics， 2014， 95(2): 141-146.	MEDICINE_RELATION	丙型肝炎	聚乙二醇化干扰素联合利巴韦林治疗24周后70％的患者获得持续病毒学应答	
聚乙二醇干扰素α-2a、聚乙二醇干扰素α-2b和利巴韦林		IFNL4	rs12979860	C/T		Muir A J， Gong L， Johnson S G， et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon‐α–Based Regimens[J]. Clinical Pharmacology & Therapeutics， 2014， 95(2): 141-146.	MEDICINE_RELATION	丙型肝炎	聚乙二醇化干扰素联合利巴韦林治疗24周后30％的患者获得持续病毒学应答	
聚乙二醇干扰素α-2a、聚乙二醇干扰素α-2b和利巴韦林		IFNL4	rs12979860	T/T		Muir A J， Gong L， Johnson S G， et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon‐α–Based Regimens[J]. Clinical Pharmacology & Therapeutics， 2014， 95(2): 141-146.	MEDICINE_RELATION	丙型肝炎	聚乙二醇化干扰素联合利巴韦林治疗24周后30％的患者获得持续病毒学应答	
第二代抗精神病药		ANKK1	rs1800497	G/G		Lawford B R， Barnes M， Swagell C D， et al. DRD2/ANKK1 Taq1A (rs 1800497 C> T) genotypes are associated with susceptibility to second generation antipsychotic-induced akathisia[J]. Journal of Psychopharmacology， 2012: 0269881112463469.	MEDICINE_RELATION	精神分裂症症状	纹状体DRD2的密度正常，服用抗精神病药不易发生静坐不能等不良反应	
第二代抗精神病药		ANKK1	rs1800497	A/G		Lawford B R， Barnes M， Swagell C D， et al. DRD2/ANKK1 Taq1A (rs 1800497 C> T) genotypes are associated with susceptibility to second generation antipsychotic-induced akathisia[J]. Journal of Psychopharmacology， 2012: 0269881112463469.	MEDICINE_RELATION	精神分裂症症状	纹状体DRD2的密度下降，服用抗精神病药较易发生静坐不能等不良反应	
第二代抗精神病药		ANKK1	rs1800497	A/A		Lawford B R， Barnes M， Swagell C D， et al. DRD2/ANKK1 Taq1A (rs 1800497 C> T) genotypes are associated with susceptibility to second generation antipsychotic-induced akathisia[J]. Journal of Psychopharmacology， 2012: 0269881112463469.	MEDICINE_RELATION	精神分裂症症状	纹状体DRD2的密度下降，服用抗精神病药较易发生静坐不能等不良反应	
伊立替康		UGT1A1	rs4148323	A/A		Onoue M， Terada T， Kobayashi M， Katsura T， Matsumoto S， Yanagihara K， et al. UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int J Clin Oncol 2009;14:136-42.Etienne‐Grimaldi M C， Boyer J C， Thomas F， et al. UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice[J]. Fundamental & clinical pharmacology， 2015， 29(3): 219-237.	MEDICINE_RELATION	抗肿瘤药物	UGT1A1的活性下降70％， 伊立替康毒性作用的发生风险增加	
伊立替康		UGT1A1	rs4148323	A/G		Onoue M， Terada T， Kobayashi M， Katsura T， Matsumoto S， Yanagihara K， et al. UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int J Clin Oncol 2009;14:136-42.Etienne‐Grimaldi M C， Boyer J C， Thomas F， et al. UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice[J]. Fundamental & clinical pharmacology， 2015， 29(3): 219-237.	MEDICINE_RELATION	抗肿瘤药物	UGT1A1的活性下降70％， 伊立替康毒性作用的发生风险增加	
伊立替康		UGT1A1	rs4148323	G/G		Onoue M， Terada T， Kobayashi M， Katsura T， Matsumoto S， Yanagihara K， et al. UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients. Int J Clin Oncol 2009;14:136-42.Etienne‐Grimaldi M C， Boyer J C， Thomas F， et al. UGT1A1 genotype and irinotecan therapy: general review and implementation in routine practice[J]. Fundamental & clinical pharmacology， 2015， 29(3): 219-237.	MEDICINE_RELATION	抗肿瘤药物	UGT1A1的活性正常， 不易发生伊立替康毒性风险	
他汀类药物		SLCO1B1	rs4149056	C/C		Link E， Parish S， Armitage J， Bowman L， Heath S， Matsuda F， et al. SLCO1B1  variants and statin-induced myopathy--a genomewide study. N Engl J Med 2008;359:789-99.de Keyser CE， Eijgelsheim M， Hofman A， Sijbrands EJ， Maitland-van DZA， van Duijn CM， et al. Single nucleotide polymorphisms in genes that are associated with a modified response to statin therapy: the Rotterdam Study. Pharmacogenomics J 2011;11:72-80.Wilke R A， Ramsey L B， Johnson S G， et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin‐induced myopathy[J]. Clinical Pharmacology & Therapeutics， 2012， 92(1): 112-117.	MEDICINE_RELATION	心血管疾病	显著降低OATP1B1对其底物的摄取能力，使他汀类药物如普伐他汀、阿托伐他汀和罗苏伐他汀等的血药浓度升高	
他汀类药物		SLCO1B1	rs4149056	C/T		Link E， Parish S， Armitage J， Bowman L， Heath S， Matsuda F， et al. SLCO1B1  variants and statin-induced myopathy--a genomewide study. N Engl J Med 2008;359:789-99.de Keyser CE， Eijgelsheim M， Hofman A， Sijbrands EJ， Maitland-van DZA， van Duijn CM， et al. Single nucleotide polymorphisms in genes that are associated with a modified response to statin therapy: the Rotterdam Study. Pharmacogenomics J 2011;11:72-80.Wilke R A， Ramsey L B， Johnson S G， et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin‐induced myopathy[J]. Clinical Pharmacology & Therapeutics， 2012， 92(1): 112-117.	MEDICINE_RELATION	心血管疾病	降低OATP1B1对其底物的摄取能力，使他汀类药物如普伐他汀、阿托伐他汀和罗苏伐他汀等的血药浓度升高	
他汀类药物		SLCO1B1	rs4149056	T/T		Link E， Parish S， Armitage J， Bowman L， Heath S， Matsuda F， et al. SLCO1B1  variants and statin-induced myopathy--a genomewide study. N Engl J Med 2008;359:789-99.de Keyser CE， Eijgelsheim M， Hofman A， Sijbrands EJ， Maitland-van DZA， van Duijn CM， et al. Single nucleotide polymorphisms in genes that are associated with a modified response to statin therapy: the Rotterdam Study. Pharmacogenomics J 2011;11:72-80.Wilke R A， Ramsey L B， Johnson S G， et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin‐induced myopathy[J]. Clinical Pharmacology & Therapeutics， 2012， 92(1): 112-117.	MEDICINE_RELATION	心血管疾病	OATP1B1对其底物的摄取能力正常，使他汀类药物如普伐他汀、阿托伐他汀和罗苏伐他汀等的血药浓度正常	
华法林-CYP4F2		CYP4F2	rs2108622	C/C		Takeuchi F， McGinnis R， Bourgeois S， Barnes C， Eriksson N， Soranzo N， et al. A genome-wide association study confirms VKORC1， CYP2C9， and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009;5:e1000433.Li J H， Ma G G， Zhu S Q， et al. Correlation between single nucleotide polymorphisms in CYP4F2 and warfarin dosing in chinese valve replacement patients[J]. Journal of cardiothoracic surgery， 2012， 7(1): 1.	MEDICINE_RELATION	抗凝药物	酶活性正常，华法林抗凝效果正常	
华法林-CYP4F2		CYP4F2	rs2108622	C/T		Takeuchi F， McGinnis R， Bourgeois S， Barnes C， Eriksson N， Soranzo N， et al. A genome-wide association study confirms VKORC1， CYP2C9， and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009;5:e1000433.Li J H， Ma G G， Zhu S Q， et al. Correlation between single nucleotide polymorphisms in CYP4F2 and warfarin dosing in chinese valve replacement patients[J]. Journal of cardiothoracic surgery， 2012， 7(1): 1.	MEDICINE_RELATION	抗凝药物	酶活性下降导致维生素K浓度升高，华法林的抗凝效果增强，可能增加出血风险	
华法林-CYP4F2		CYP4F2	rs2108622	T/T		Takeuchi F， McGinnis R， Bourgeois S， Barnes C， Eriksson N， Soranzo N， et al. A genome-wide association study confirms VKORC1， CYP2C9， and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009;5:e1000433.Li J H， Ma G G， Zhu S Q， et al. Correlation between single nucleotide polymorphisms in CYP4F2 and warfarin dosing in chinese valve replacement patients[J]. Journal of cardiothoracic surgery， 2012， 7(1): 1.	MEDICINE_RELATION	抗凝药物	酶活性下降导致维生素K浓度升高，华法林的抗凝效果增强，出血的风险显著增加较显著	
氯沙坦		CYP2C9	rs1057910	A/A		Yasar ?， Tybring G， Hidestrand M， et al. Role of CYP2C9 polymorphism in losartan oxidation[J]. Drug metabolism and disposition， 2001， 29(7): 1051-1056.Yasar ?， Forslund‐Bergengren C， Tybring G， et al. Pharmacokinetics of losartan and its metabolite E‐3174 in relation to the CYP2C9 genotype[J]. Clinical Pharmacology & Therapeutics， 2002， 71(1): 89-98.	MEDICINE_RELATION	抗高血压药物	服用氯沙坦后E-3174的生成正常，氯沙坦的代谢率正常	
氯沙坦		CYP2C9	rs1057910	A/C		Yasar ?， Tybring G， Hidestrand M， et al. Role of CYP2C9 polymorphism in losartan oxidation[J]. Drug metabolism and disposition， 2001， 29(7): 1051-1056.Yasar ?， Forslund‐Bergengren C， Tybring G， et al. Pharmacokinetics of losartan and its metabolite E‐3174 in relation to the CYP2C9 genotype[J]. Clinical Pharmacology & Therapeutics， 2002， 71(1): 89-98.	MEDICINE_RELATION	抗高血压药物	服用氯沙坦后E-3174的生成减少，氯沙坦的代谢率降低	
氯沙坦		CYP2C9	rs1057910	C/C		Yasar ?， Tybring G， Hidestrand M， et al. Role of CYP2C9 polymorphism in losartan oxidation[J]. Drug metabolism and disposition， 2001， 29(7): 1051-1056.Yasar ?， Forslund‐Bergengren C， Tybring G， et al. Pharmacokinetics of losartan and its metabolite E‐3174 in relation to the CYP2C9 genotype[J]. Clinical Pharmacology & Therapeutics， 2002， 71(1): 89-98.	MEDICINE_RELATION	抗高血压药物	服用氯沙坦后E-3174的生成减少，氯沙坦的代谢率降低	
塞来昔布		CYP2C9	rs1057910	A/A		Kirchheiner J， St?rmer E， Meisel C， et al. Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites[J]. Pharmacogenetics and Genomics， 2003， 13(8): 473-480.Agúndez J A G， García-Martín E， Martínez C. Genetically based impairment in CYP2C8-and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?[J]. Expert opinion on drug metabolism & toxicology， 2009， 5(6): 607-620.	MEDICINE_RELATION	抗炎药	塞来昔布在肝脏中由CYP2C9代谢正常，不易引起不良反应	
塞来昔布		CYP2C9	rs1057910	A/C		Kirchheiner J， St?rmer E， Meisel C， et al. Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites[J]. Pharmacogenetics and Genomics， 2003， 13(8): 473-480.Agúndez J A G， García-Martín E， Martínez C. Genetically based impairment in CYP2C8-and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?[J]. Expert opinion on drug metabolism & toxicology， 2009， 5(6): 607-620.	MEDICINE_RELATION	抗炎药	塞来昔布在肝脏中由CYP2C9代谢较差，较易引起不良反应	
塞来昔布		CYP2C9	rs1057910	C/C		Kirchheiner J， St?rmer E， Meisel C， et al. Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites[J]. Pharmacogenetics and Genomics， 2003， 13(8): 473-480.Agúndez J A G， García-Martín E， Martínez C. Genetically based impairment in CYP2C8-and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?[J]. Expert opinion on drug metabolism & toxicology， 2009， 5(6): 607-620.	MEDICINE_RELATION	抗炎药	塞来昔布在肝脏中由CYP2C9代谢较差，较易引起不良反应	
华法林-CYP2C9		CYP2C9	rs1057910	A/A		Aithal GP， Day CP， Kesteven PJ， Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999;353:717-9.Takeuchi F， McGinnis R， Bourgeois S， Barnes C， Eriksson N， Soranzo N， et al. A genome-wide association study confirms VKORC1， CYP2C9， and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009;5:e1000433.King B P， Khan T I， Aithal G P， et al. Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism[J]. Pharmacogenetics and Genomics， 2004， 14(12): 813-822.	MEDICINE_RELATION	抗凝药物	基因型个体S-华法林的口服清除率正常	
华法林-CYP2C9		CYP2C9	rs1057910	A/C		Aithal GP， Day CP， Kesteven PJ， Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999;353:717-9.Takeuchi F， McGinnis R， Bourgeois S， Barnes C， Eriksson N， Soranzo N， et al. A genome-wide association study confirms VKORC1， CYP2C9， and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009;5:e1000433.King B P， Khan T I， Aithal G P， et al. Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism[J]. Pharmacogenetics and Genomics， 2004， 14(12): 813-822.	MEDICINE_RELATION	抗凝药物	基因型个体S-华法林的口服清除率下降，血药浓度可能升高	
华法林-CYP2C9		CYP2C9	rs1057910	C/C		Aithal GP， Day CP， Kesteven PJ， Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999;353:717-9.Takeuchi F， McGinnis R， Bourgeois S， Barnes C， Eriksson N， Soranzo N， et al. A genome-wide association study confirms VKORC1， CYP2C9， and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 2009;5:e1000433.King B P， Khan T I， Aithal G P， et al. Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism[J]. Pharmacogenetics and Genomics， 2004， 14(12): 813-822.	MEDICINE_RELATION	抗凝药物	基因型个体S-华法林的口服清除率下降，血药浓度可能升高	
乙醇		ALDH2	rs671	G/G		Yoshida A， Huang I Y， Ikawa M. Molecular abnormality of an inactive aldehyde dehydrogenase variant commonly found in Orientals[J]. Proceedings of the National Academy of Sciences， 1984， 81(1): 258-261.	MEDICINE_RELATION		乙醇代谢能力正常	
乙醇		ALDH2	rs671	A/G		Yoshida A， Huang I Y， Ikawa M. Molecular abnormality of an inactive aldehyde dehydrogenase variant commonly found in Orientals[J]. Proceedings of the National Academy of Sciences， 1984， 81(1): 258-261.	MEDICINE_RELATION		乙醇代谢能力下降	
乙醇		ALDH2	rs671	A/A		Yoshida A， Huang I Y， Ikawa M. Molecular abnormality of an inactive aldehyde dehydrogenase variant commonly found in Orientals[J]. Proceedings of the National Academy of Sciences， 1984， 81(1): 258-261.	MEDICINE_RELATION		乙醇代谢能力下降	
硝酸甘油		ALDH2	rs671	G/G		Zhang H， Chen Y G， Xu F， et al. [The relationship between aldehyde dehydrogenase-2 gene polymorphisms and efficacy of nitroglycerin][J]. Zhonghua nei ke za zhi， 2007， 46(8): 629-632.	MEDICINE_RELATION	抗心肌缺血	代谢硝酸甘油的能力正常，硝酸甘油抗心肌缺血的效应正常	
硝酸甘油		ALDH2	rs671	G/A		Zhang H， Chen Y G， Xu F， et al. [The relationship between aldehyde dehydrogenase-2 gene polymorphisms and efficacy of nitroglycerin][J]. Zhonghua nei ke za zhi， 2007， 46(8): 629-632.	MEDICINE_RELATION	抗心肌缺血	代谢硝酸甘油的能力下降，硝酸甘油抗心肌缺血的效应减弱	
硝酸甘油		ALDH2	rs671	A/A		Zhang H， Chen Y G， Xu F， et al. [The relationship between aldehyde dehydrogenase-2 gene polymorphisms and efficacy of nitroglycerin][J]. Zhonghua nei ke za zhi， 2007， 46(8): 629-632.	MEDICINE_RELATION	抗心肌缺血	代谢硝酸甘油的能力下降，硝酸甘油抗心肌缺血的效应减弱	
他克莫司		CYP3A5	rs776746	T/T		Birdwell K A， Decker B， Barbarino J M， et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing[J]. Clinical Pharmacology & Therapeutics， 2015， 98(1): 19-24.	MEDICINE_RELATION	免疫抑制剂	他克莫司的代谢正常	
他克莫司		CYP3A5	rs776746	T/C		Birdwell K A， Decker B， Barbarino J M， et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing[J]. Clinical Pharmacology & Therapeutics， 2015， 98(1): 19-24.	MEDICINE_RELATION	免疫抑制剂	酶活性降低导致他克莫司的血药浓度升高，不良反应增加	
他克莫司		CYP3A5	rs776746	C/C		Birdwell K A， Decker B， Barbarino J M， et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP3A5 genotype and tacrolimus dosing[J]. Clinical Pharmacology & Therapeutics， 2015， 98(1): 19-24.	MEDICINE_RELATION	免疫抑制剂	酶活性降低导致他克莫司的血药浓度升高，不良反应增加	
